Anti-MUC16 antibodies and uses thereof
Antibodies targeting the non-shed extracellular domain of MUC16 with defined CDRs provide a therapeutic solution for ovarian cancer by enhancing binding and inhibiting tumor cell invasion.
Patent Information
- Application Number
- CA2979976
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-03-17
- Filing Date
- 2016-03-16
- Publication Date
- 2026-11-03
- Estimated Expiration
- 2036-03-16
AI Technical Summary
Existing antibodies targeting MUC16, a mucin protein overexpressed in ovarian carcinomas, primarily bind to the secreted form, limiting their utility as therapeutic targets, as they do not effectively engage the retained extracellular fraction.
Development of antibodies and antigen-binding fragments that specifically target epitopes within the non-shed, extracellular portion of MUC16, particularly focusing on glycosylation sites like Asn1806, with defined complementarity determining regions (CDRs) to enhance binding and therapeutic potential.
These antibodies effectively bind to the retained extracellular domain of MUC16, inhibiting tumor cell invasion and growth, offering a novel approach for ovarian cancer therapy.
Abstract
Description
ANTI-MUC16 ANTIBODIES AND USES THEREOF
[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 134,402, filed on March 17, 2015.
[0002] 1. FIELD
[0003] Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind to MUC16, a tethered mucin protein, and modulate expression and / or activity of MUC16 for managing, treating, or preventing disorders, such as cancer. 2. BACKGROUND
[0004] Mucins are important biomolecules for cellular homeostasis and protection of epithelial surfaces. Changes to expression of mucins in ovarian cancer might be exploited in diagnosis, prognosis and treatment (Singh AP, et al. Lancet Oncol 2008;9(11):1076-85). MUC16 is one such mucin which is over expressed on most ovarian carcinomas and is an established surrogate serum marker (CA-125) for the detection and progression of ovarian cancers (Badgwell D, et al., Dis Markers 2007;23(5-6):397410; Bast RC, Jr, et al., Int J Gynecol Cancer 2005;15 Suppl 3:274-81; Fritsche HA, et al., Clin Chem 1998;44(7):1379-80; and Krivak TC, et al., Gynecol Oncol 2009;115(1):81-5). MUC16 is a highly glycosylated mucin composed of a large cleaved and released domain, termed CA-125, consisting of multiple repeat sequences, and a retained domain (MUC-CD) which includes a residual non-repeating extracellular fragment, a transmembrane domain, and a cytoplasmic tail (O'Brien TJ, et al. Tumour Biol 2001;22(6):348-66). Since the antigen is otherwise only expressed at low levels in the uterus, endometrium, fallopian tubes, ovaries, and serosa of the abdominal and thoracic cavities, MUC16 is a potentially attractive target for immune-based therapies.
[0005] However, the fact that most of the extracellular domain of MUC16 is cleaved and secreted limits the utility of MUC16 as a target antigen on ovarian carcinomas. In fact, to date, most reported MUC16 monoclonal antibodies bind to epitopes present on the large secreted CA- 125 fraction of the glycoprotein, with none known to bind to the retained extra-cellular fraction (MUC-CD) of the antigen (Bellone S, Am J Obstet Gynecol 2009;200(1):75 el-10, Berek JS. Expert Opin Biol Ther 2004;4(7):1159-65; O'Brien TJ, et al. Int J Biol Markers 1998;13(4):188- 95). Thus, the generation of new antibodies to the non-shed region of MUC16 are needed for diagnostic and therapeutic approaches. 3. SUMMARY
[0006] Provided are antibodies and antigen-binding fragments thereof, and polypeptides including such antibodies or antigen-binding fragments, such as fusion proteins, conjugates, and / or chimeric antigen receptors, as well as cells expressing the same. Among the antibodies and antigen-binding fragments are those that specifically bind to epitopes of a MUC16 protein. Such antibodies are referred to herein as "MUC16 Glycosylation Antibodies". Such epitopes are typically epitopes within or substantially within an extracellular portion of a MUC16 molecule, generally a non-shed form of MUC16; in some embodiments, the epitope is not within, or the antibody or fragment does not bind to, a tandem repeat region of MUC16 and / or a secreted form of MUC16. In some embodiments, the epitope is within or includes residues within MUC16c114, and typically includes one or more glycosylated residues or glycosylation sites therein. In some embodiments, the epitope includes one or more glycosylation sites, such as sites for N-glycosylation. In some aspects, the epitope includes an asparagine residue corresponding to Asn1806 or Asn1800 of the MUC16 sequence set forth in SEQ ID NO: 150 (and / or a glycosylated form(s) thereof); in some aspects, the epitope includes an asparagine residue corresponding to Asn1806 of SEQ ID NO: 150, but does not include an asparagine residue corresponding to Asn1800 of SEQ ID NO: 150; in some aspects, the epitope includes an asparagine residue corresponding to Asn1800 of SEQ ID NO: 150, but does not include an asparagine residue corresponding to Asn1806 of SEQ ID NO: 150. In some of any of such embodiments, such one or more asparagine is glycosylated, such as N-glycosylated. In some embodiments, the antibody or antigen-binding fragment binds to an epitope within or that includes residues within SEQ ID NO: 131; binds to an epitope within or that includes residues within SEQ ID NO: 130, or a combination thereof; in some embodiments, the antibody or fragment does not immunospecifically bind within a region of MUC16 corresponding to SEQ ID NO: 168, or within residues 2-19 of SEQ ID NO: 168.
[0007] In some embodiments, the provided antibodies or antigen-binding fragments include one or more complementarity determining regions (CDRs) corresponding to CDRs of the heavy chain and / or the light chain of an antibody sequence, such as a MUC16-glycosylation site- targeted antibody sequence, described herein, such as of the antibody designated 18C6, of the antibody designated 10C6, and / or of the antibody designated 19C11. In some embodiments, the antibody or fragment has a heavy chain CDR3 (HCDR3) having a sequence corresponding to an HCDR3 of one of the heavy chain sequences provided herein, such as of the heavy chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the HCDR3 has a sequence selected from among IGTAQATDALDY (SEQ ID NO:105), GTAQATDALD (SEQ ID NO:111); X<com:Sub>18< / com:Sub>RIGTAQATDALDY (SEQ ID NO:117), wherein X<com:Sub>18< / com:Sub> is T, A, or S; SEQ ID NO: 5; SEQ ID NO: 25; SEQ ID NO: 45; SEQ ID NO: 65; and SEQ ID NO: 85; SEQ ID NO: 31, 51, 71, and 91; SEQ ID NO: 17; SEQ ID ON: 37; SEQ ID NO: 57; SEQ ID NO: 77; and SEQ ID NO: 97.
[0008] In some embodiments, the provided antibodies or antigen-binding fragments include a heavy chain CDR1 (HCDR1) having a sequence corresponding to an HCDR1 of one of the heavy chain sequences provided herein, such as of the heavy chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the HCDR1 has a sequence selected from among TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein X<com:Sub>1< / com:Sub> is L or V, sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein X<com:Sub>8< / com:Sub> is N or S, and wherein X<com:Sub>9< / com:Sub> is L or V, GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L, and the sequence set forth as SEQ ID NO: 3; and the sequence set forth as SEQ ID NO: 9; and the sequence set forth as SEQ ID NO: 15; and the sequence set forth in any of SEQ ID NOs: 23, 43, 63, 83; and the sequence set forth in any of SEQ ID NOs: 29, 49, 69, and 89; and the sequence set forth in any of SEQ ID NOs: 35, 55, 75, and 95.
[0009] In some embodiments, the provided antibodies or antigen-binding fragments include a heavy chain CDR2 (HCDR2) having a sequence corresponding to an HCDR2 of one of the heavy chain sequences provided herein, such as of the heavy chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the HCDR2 has a sequence selected from among HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein X<com:Sub>2< / com:Sub> is E or absent, and X<com:Sub>3< / com:Sub> is Y or N; WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; the sequence set forth as SEQ ID NO: 4; the sequence set forth as SEQ ID NO: 10; and the sequence set forth as SEQ ID NO: 16; and the sequence set forth in any of SEQ ID NOs: 24, 44, 64, 84; and the sequence set forth in any of SEQ ID NOs: 30, 50, 70, 90; and the sequence set forth in any of SEQ ID NOs: 36, 56, 76, 96.
[0010] In some embodiments, including any of the aforementioned embodiments, the provided antibodies or antigen-binding fragments include, e.g., further include, a light chain CDR3 (LCDR3) having a sequence corresponding to an LCDR3 of one of the light chain sequences provided herein, such as of the light chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the LCDR3 has a sequence selected from among MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein X<com:Sub>6< / com:Sub> is G or S and wherein X<com:Sub>7< / com:Sub> is H or Y; <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114) wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and wherein <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y; and MQSLEYPLT (SEQ ID NO:120); a sequence selected from among SEQ ID NOs: 8, 28, 48, 68, and 88; a sequence selected from among SEQ ID NOs: 14, 34, 54, 74, and 94; and a sequence selected from among SEQ ID NOs: 20, 4, 60, 80, and 100.
[0011] In some embodiments, including any of the aforementioned embodiments, the provided antibodies or antigen-binding fragments include, e.g., further include, a light chain CDR1 (LCDR1) having a sequence corresponding to an LCDR1 of one of the light chain sequences provided herein, such as of the light chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the LCDR1 has a sequence selected from among RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106); SKSLX<com:Sub>11< / com:Sub>X<com:Sub>12< / com:Sub>SNGNTY (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and wherein <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; KSLX<com:Sub>19< / com:Sub>X<com:Sub>20< / com:Sub>SNGNTY (SEQ ID NO:118), wherein <com:Math><semantics>X19<annotation encoding="application / x-tex">X_{19}< / annotation>< / semantics>< / com:Math> is V or L, and wherein <com:Math><semantics>X20<annotation encoding="application / x-tex">X_{20}< / annotation>< / semantics>< / com:Math> is H or K; a sequence selected from among SEQ ID NOs: 6, 26, 46, 66, and 86; a sequence selected from among SEQ ID NOs: 12, 32, 52, 72, and 92; and a sequence selected from among SEQ ID NOs: 18, 38, 58, 78, and 98.
[0012] In some embodiments, including any of the aforementioned embodiments, the provided antibodies or antigen-binding fragments include, e.g., further include, a light chain CDR2 (LCDR2) having a sequence corresponding to an LCDR2 of one of the light chain sequences provided herein, such as of the light chain sequences of the antibody designated 18C6, of the antibody designated 10C6, of the antibody designated 19C11, and / or of the antibody designated 7B12. In some aspects, the LCDR2 has a sequence selected from among YMSNLAS (SEQ ID NO:107); YMS (SEQ ID NO:113); and the sequence set forth in any of SEQ ID NOs: 7, 27, 47, 67, 87; 13, 33, 53, 73, 93, 19, 39, 59, 79, 99, 119.
[0013] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) a VH complementarity determining region (CDR)1 comprising the amino acid sequence <com:Math><semantics>TX1GMGVG<annotation encoding="application / x-tex">TX_1GMGVG< / annotation>< / semantics>< / com:Math> (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein X<com:Sub>2< / com:Sub> is E or absent, and X<com:Sub>3< / com:Sub> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO: 105).
[0014] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein X<com:Sub>8< / com:Sub> is N or S, and wherein X<com:Sub>9< / com:Sub> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111).
[0015] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein X<com:Sub>15< / com:Sub> is N or S, and X<com:Sub>16< / com:Sub> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and(c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S.
[0016] Among the antibodies and antigen-binding fragments of any of the embodiments are those having a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; aVH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97.
[0017] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein <com:Math><semantics>X4<annotation encoding="application / x-tex">X_4< / annotation>< / semantics>< / com:Math> is R or L, and <com:Math><semantics>X5<annotation encoding="application / x-tex">X_5< / annotation>< / semantics>< / com:Math> is K or H; (b) a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and (c) a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein X<com:Sub>6< / com:Sub> is G or S, and X<com:Sub>7< / com:Sub> is H or Y.
[0018] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) a VL CDR1 comprising the amino acid sequence <com:Math><semantics>SKSLX11X12SNGNTY<annotation encoding="application / x-tex">SKSLX_{11}X_{12}SNGNTY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and (c) a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y.
[0019] Among the antibodies and antigen-binding fragments of any of the embodiments are those having a VL CDR1 comprising the amino acid sequence <com:Math><semantics>KSLX19X20SNGNTY<annotation encoding="application / x-tex">KSLX_{19}X_{20}SNGNTY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:118), wherein <com:Math><semantics>X19<annotation encoding="application / x-tex">X_{19}< / annotation>< / semantics>< / com:Math> is V or L, and <com:Math><semantics>X20<annotation encoding="application / x-tex">X_{20}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and (c) a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120).
[0020] Among the antibodies and antigen-binding fragments of any of the embodiments are those having a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74; or a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
[0021] Among the antibodies and antigen-binding fragments of any of the embodiments are those having (a) (i) a VH comprising a VH CDR1 comprising the amino acid sequence <com:Math><semantics>TX1GMGVG<annotation encoding="application / x-tex">TX_1GMGVG< / annotation>< / semantics>< / com:Math> (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein X<com:Sub>2< / com:Sub> is E or absent, and X<com:Sub>3< / com:Sub> is Y or N; and a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein X<com:Sub>4< / com:Sub> is R or L, and X<com:Sub>5< / com:Sub> is K or H; a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein X<com:Sub>6< / com:Sub> is G or S, and <com:Math><semantics>X7<annotation encoding="application / x-tex">X_7< / annotation>< / semantics>< / com:Math> is H or Y; or (b) (i) a VH comprising a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein X<com:Sub>8< / com:Sub> is N or S, and wherein X<com:Sub>9< / com:Sub> is L or V; a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence SKSLX<com:Sub>11< / com:Sub>X<com:Sub>12< / com:Sub>SNGNTY (SEQ ID NO:112), wherein X<com:Sub>11< / com:Sub> is L or R, and X<com:Sub>12< / com:Sub> is H or K; a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y; or (c) (i) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein X<com:Sub>15< / com:Sub> is N or S, and X<com:Sub>16< / com:Sub> is V or L; a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence KSLX<com:Sub>19< / com:Sub>X<com:Sub>20< / com:Sub>SNGNTY (SEQ ID NO:118), wherein X<com:Sub>19< / com:Sub> is V or L, and X<com:Sub>20< / com:Sub> is H or K; a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120); or (d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28; or (e) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34; or (f) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40; or (g) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48; or (h) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54; or (i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60; or (j) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88; or (k) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94; or (l) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100; or (m) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8; or (n) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14; or (o) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or (p) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68; or (q) (i) a VH comprising aVH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74; or (r) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
[0022] Among the antibodies and antigen-binding fragments of any of the embodiments are those having: (a) (i) a VH comprising the amino acid sequence of QVX<com:Sub>21< / com:Sub>LKESGPGX<com:Sub>22< / com:Sub>LQPSQTLSLTCSFSGFSLX<com:Sub>23< / com:Sub>TX<com:Sub>24< / com:Sub>GMGVGWX<com:Sub>25< / com:Sub>RQX<com:Sub>26< / com:Sub>SGKGLEWLAH IWWDDX<com:Sub>27< / com:Sub>DKYYX<com:Sub>28< / com:Sub>PALKSRLTISX<com:Sub>29< / com:Sub>X<com:Sub>30< / com:Sub>X<com:Sub>31< / com:Sub>SKNQVFLKIX<com:Sub>32< / com:Sub>NVX<com:Sub>33< / com:Sub>TADX<com:Sub>34< / com:Sub>ATYYCX<com:Sub>35< / com:Sub>RI GTAQATDALDYWGQGTSVTVSS (SEQ ID NO:101), wherein X<com:Sub>21< / com:Sub> is T or N, X<com:Sub>22< / com:Sub> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A; and (ii) a VL comprising the amino acid sequence of DIVMTQAAPSX<com:Sub>36< / com:Sub>X<com:Sub>37< / com:Sub>VTPGESVSISCRSSKSLX<com:Sub>38< / com:Sub>X<com:Sub>39< / com:Sub>SNGNTYLYWFLQRPGQSPQRLIYY MSNLASGVPDRFSGRGSGTDFTLX<com:Sub>40< / com:Sub>ISRVEAX<com:Sub>41< / com:Sub>DVGVYYCMQX<com:Sub>42< / com:Sub>LEX<com:Sub>43< / com:Sub>PLTFGGGTKL EIK (SEQ ID NO:102), wherein X<com:Sub>36< / com:Sub> is I or V, X<com:Sub>37< / com:Sub> is P or S, X<com:Sub>38< / com:Sub> is R or L, X<com:Sub>39< / com:Sub> is K or H, X<com:Sub>40< / com:Sub> is R or K, X<com:Sub>41< / com:Sub> is E or G, X<com:Sub>42< / com:Sub> is S or G, and X<com:Sub>43< / com:Sub> is Y or H; or (b) (i) a VH comprising the amino acid sequence of SEQ ID NO:1; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:2; or (c) (i) a VH comprising the amino acid sequence of SEQ ID NO:21; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:22; or (d) (i) a VH comprising the amino acid sequence of SEQ ID NO:41; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:42; or (e) (i) a VH comprising the amino acid sequence of SEQ ID NO:61; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:62; or (f) (i) a VH comprising the amino acid sequence of SEQ ID NO:81; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:82.
[0023] Also among the provided antibodies or antigen-binding fragments are those having at least 90, 95, 96, 97, 98, 99, or 100 % identity with the VH and / or VL sequence(s) of any such antibodies and / or of any of the antibodies set forth in Tables 1 and 2. Also among the provided antibodies and fragments thereof are those that compete for binding to MUC16 and / or an epitope thereof with any of such antibodies.
[0024] Also provided are fusion proteins, such as chimeric molecules, and / or conjugates, comprising any of the antibodies, such as chimeric antigen receptors (CARs) containing such antibodies or fragments, and cells epressing such molecules. Also provided are humanized versions of any such antibodies.
[0025] In some embodiments, provided herein is an antibody or an antigen-binding fragment thereof, wherein the antibody (a) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (b) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (c) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16. In certain embodiments, (i) the cell recombinantly expressing the first form of MUC16 is a SKOV3 cell; (ii) the cell recombinantly expressing the second form of MUC16 is a SKOV3 cell; and (iii) the cells in step (c) are SKOV3 cells. In a specific embodiment, the antibody lacks immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139. In certain embodiments, (i) the cell recombinantly expressing the first form of MUC16 is a SKOV3 cell; (ii) the cell recombinantly expressing the second form of MUC16 is a SKOV3 cell; and (iii) the cells in step (c) are SKOV3 cells. In certain embodiments, (i) the cell recombinantly expressing the first form of MUC16 is a SKOV3 cell; (ii) the cell recombinantly expressing the second form of MUC16 is a SKOV3 cell; (iii) the cell recombinantly expressing the third form of MUC16 is a SKOV3 cell; and (iv) the cells in step (c) are SKOV3 cells.
[0026] Also provided herein is an antibody or an antigen-binding fragment thereof, wherein the antibody (a) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (b) lacks immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (c) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16. In certain embodiments, (i) the cell recombinantly expressing the first form of MUC16 is a SKOV3 cell; (ii) the cell recombinantly expressing the third form of MUC16 is a SKOV3 cell; and (iii) the cells in step (c) are SKOV3 cells.
[0027] In certain embodiments the antibody or antigen-binding fragment thereof immunospecifically binds to an epitope comprising N-glycosylated asparagine 1806 of SEQ ID NO: 150.
[0028] In certain embodiments, the antibody or antigen-binding fragment thereof immunospecifically binds to the amino acid sequence CTRNGTQLQNFTLDRSSV (SEQ ID NO:130), wherein amino acid residue number 4 (N4) and amino acid residue number 10 (N10) of CTRNGTQLQNFTLDRSSV (SEQ ID NO:130) are glycosylated. In certain embodiments, the antibody or antigen-binding fragment thereof immunospecifically binds to the amino acid sequence CGTQLQNFTLDRSSV (SEQ ID NO:131), wherein amino acid residue number 7 (N7) of CGTQLQNFTLDRSSV (SEQ ID NO:131) is glycosylated. In certain embodiments, the glycosylation consists of an N-linked chitobiose.
[0029] In certain embodiments, the antibody or antigen-binding fragment thereof is internalized into a cell expressing the first form of MUC16 upon contacting the cell with the antibody or antigen-binding fragment. In certain embodiments, the cell is a SKOV3 cell that recombinantly expresses the first form of MUC16.
[0030] In certain embodiments, the antibody or antigen-binding fragment thereof inhibits growth of a tumor that expresses a glycosylated form of MUC16.
[0031] In certain embodiments, the antibody is a monoclonal antibody.
[0032] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), which comprises (a) a VH complementarity determining region (CDR)1 comprising the amino acid sequence TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein X<com:Sub>1< / com:Sub> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein X<com:Sub>2< / com:Sub> is E or absent, and X<com:Sub>3< / com:Sub> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105).
[0033] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein X<com:Sub>8< / com:Sub> is N or S, and wherein X<com:Sub>9< / com:Sub> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111).
[0034] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein X<com:Sub>15< / com:Sub> is N or S, and X<com:Sub>16< / com:Sub> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S.
[0035] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5.
[0036] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11.
[0037] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17.
[0038] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25.
[0039] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31.
[0040] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37.
[0041] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45.
[0042] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51.
[0043] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57.
[0044] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65.
[0045] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71.
[0046] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77.
[0047] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85.
[0048] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91.
[0049] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97.
[0050] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] GTAQATDALDYWGQGTSVTVSS (SEQ ID NO:101), wherein X<com:Sub>21< / com:Sub> is T or N, X<com:Sub>22< / com:Sub> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A.
[0051] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:1.
[0052] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:21.
[0053] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:41.
[0054] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:61.
[0055] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:81.
[0056] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL), which comprises (a) a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein X<com:Sub>4< / com:Sub> is R or L, and X<com:Sub>5< / com:Sub> is K or H; (b) a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and (c) a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein X<com:Sub>6< / com:Sub> is G or S, and <com:Math><semantics>X7<annotation encoding="application / x-tex">X_7< / annotation>< / semantics>< / com:Math> is H or Y.
[0057] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises (a) a VL CDR1 comprising the amino acid sequence SKSLX<com:Sub>11< / com:Sub>X<com:Sub>12< / com:Sub>SNGNTY (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and (c) a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y.
[0058] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises (a) a VL CDR1 comprising the amino acid sequence <com:Math><semantics>KSLX19X20SNGNTY<annotation encoding="application / x-tex">KSLX_{19}X_{20}SNGNTY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:118), wherein <com:Math><semantics>X19<annotation encoding="application / x-tex">X_{19}< / annotation>< / semantics>< / com:Math> is V or L, and <com:Math><semantics>X20<annotation encoding="application / x-tex">X_{20}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and (c) a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120).
[0059] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (VL), which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28.
[0060] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34.
[0061] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40.
[0062] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48.
[0063] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54.
[0064] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60.
[0065] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88.
[0066] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94.
[0067] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100.
[0068] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8.
[0069] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14.
[0070] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20.
[0071] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68.
[0072] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74.
[0073] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
[0074] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of DIVMTQAAPSX<com:Sub>36< / com:Sub>X<com:Sub>37< / com:Sub>VTPGESVSISCRSSKSLX<com:Sub>38< / com:Sub>X<com:Sub>39< / com:Sub>SNGNTYLYWFLQRPGQSPQRLIYY MSNLASGVPDRFSGRGSGTDFTLX<com:Sub>40< / com:Sub>ISRVEAX<com:Sub>41< / com:Sub>DVGVYYCMQX<com:Sub>42< / com:Sub>LEX<com:Sub>43< / com:Sub>PLTFGGGTKL EIK (SEQ ID NO:102), wherein <com:Math><semantics>X36<annotation encoding="application / x-tex">X_{36}< / annotation>< / semantics>< / com:Math> is I or V, <com:Math><semantics>X37<annotation encoding="application / x-tex">X_{37}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X38<annotation encoding="application / x-tex">X_{38}< / annotation>< / semantics>< / com:Math> is R or L, <com:Math><semantics>X39<annotation encoding="application / x-tex">X_{39}< / annotation>< / semantics>< / com:Math> is K or H, <com:Math><semantics>X40<annotation encoding="application / x-tex">X_{40}< / annotation>< / semantics>< / com:Math> is R or K, <com:Math><semantics>X41<annotation encoding="application / x-tex">X_{41}< / annotation>< / semantics>< / com:Math> is E or G, <com:Math><semantics>X42<annotation encoding="application / x-tex">X_{42}< / annotation>< / semantics>< / com:Math> is S or G, and <com:Math><semantics>X43<annotation encoding="application / x-tex">X_{43}< / annotation>< / semantics>< / com:Math> is Y or H.
[0075] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:22.
[0076] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:42.
[0077] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:82.
[0078] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:2.
[0079] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:62.
[0080] In certain embodiments, the antibody comprises human-derived heavy and light chain constant regions. In certain embodiments, the heavy chain constant region has an isotype selected from the group consisting of gamma1, gamma2, gamma3, and gamma4. In certain embodiments, the light chain constant region has an isotype selected from the group consisting of kappa and lambda.
[0081] In certain embodiments, the antibody or antigen-binding fragment thereof is humanized. In certain embodiments, the antibody or antigen-binding fragment thereof is a humanized form of a rodent antibody.
[0082] In certain embodiments, the antibody is an immunoglobulin comprising two identical heavy chains and two identical light chains. In certain embodiments, the immunoglobulin is an IgG.
[0083] Also provided herein is an antibody conjugate comprising an antibody or antigen- binding fragment thereof provided herein conjugated to an agent. In certain embodiments, the agent is an imaging agent or a cytotoxic agent.
[0084] In certain embodiments, the antibody or antigen-binding fragment thereof is a bispecific antibody. In certain embodiments, the bispecific antibody immunospecifically binds CD3. In certain embodiments, the bispecific antibody comprises an immunoglobulin that immunospecifically binds MUC16, wherein the light chain of the immunoglublin is conjugated via a peptide linker to a single chain variable fragment (scFv) that immunospecifically binds CD3. Also provided herein is a bispecific antibody conjugate comprising a bispecific antibody provided herein conjugated to an agent. In certain embodiments, the agent is an imaging agent or a cytotoxic agent.
[0085] In certain embodiments, the antigen-binding fragment thereof is a single chain variable fragment (scFv). Also provided herein is a scFv conjugate comprising a scFv provided herein conjugated to an agent. In certain embodiments, the agent is an imaging agent or a cytotoxic agent.
[0086] Also provided herein are fusion proteins, chimeric molecules, and conjugates comprising the antibodies and antigen-binding fragments. Provided are chimeric antigen receptors (CARs) including one or more of any of the provided antibodies or antigen-binding fragments thereof, such as a CAR comprising any of the scFvs provided herein or a scFv conjugate provided herein; and / or CARs comprising antigen-binding domains that compete for binding to MUC16 therewith.
[0087] Also provided herein is an antibody heavy chain or an antigen-binding portion thereof. Among the provided antibodies and antigen-binding fragments thereof are those having heavy chains and / or antigen-binding portions thereof such as VH regions thereof; also provided are such heavy chains and antigen-binding portions thereof. In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises (a) a VH CDR1 comprising the amino acid sequence <com:Math><semantics>TX1GMGVG<annotation encoding="application / x-tex">TX_1GMGVG< / annotation>< / semantics>< / com:Math> (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein X<com:Sub>2< / com:Sub> is E or absent, and X<com:Sub>3< / com:Sub> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[8800] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> is N or S, and <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0089] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math>RIGTAQATDALDY (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S; wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0090] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0091] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0092] In some embodiments, the heavy chain or antigen-binding portions thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0093] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0094] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0095] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0096] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0097] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0098] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[0099] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00100] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00101] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00102] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00103] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00104] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH, which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00105] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of [Image disponible dans le document PDF, Image available in the PDF document] IWWDDX<com:Sub>27< / com:Sub>DKYYX<com:Sub>28< / com:Sub>PALKSRLTISX<com:Sub>29< / com:Sub>X<com:Sub>30< / com:Sub>X<com:Sub>31< / com:Sub>SKNQVFLKIX<com:Sub>32< / com:Sub>NVX<com:Sub>33< / com:Sub>TADX<com:Sub>34< / com:Sub>ATYYCX<com:Sub>35< / com:Sub>RI GTAQATDALDYWGQGTSVTVSS (SEQ ID NO:101), wherein X<com:Sub>21< / com:Sub> is T or N, X<com:Sub>22< / com:Sub> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00106] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:1, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00107] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:21, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00108] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:41, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00109] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:61, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00110] In some embodiments, the heavy chain or antigen-binding portion thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:81, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody heavy chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00111] In certain embodiments, the antibody heavy chain or antigen-binding portion thereof comprises a human-derived heavy chain constant region. In certain embodiments, the heavy chain constant region has an isotype selected from the group consisting of gamma1, gamma2, gamma3, and gamma4. In certain embodiments, the antibody heavy chain is humanized. In certain embodiments, the antibody heavy chain is a humanized form of a rodent heavy chain.
[00112] Also provided herein is an antibody heavy chain conjugate comprising an antibody heavy chain provided herein, wherein said antibody heavy chain is conjugated to an agent. In certain embodiments, the agent is an imaging agent or a cytotoxic agent.
[00113] Among the provided antibodies and antigen-binding fragments thereof are those having light chains and / or portions thereof such as VL regions thereof; also provided are such light chains and antigen-binding portions thereof. In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises (a) a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein X<com:Sub>4< / com:Sub> is R or L, and X<com:Sub>5< / com:Sub> is K or H; (b) a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and (c) a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein <com:Math><semantics>X6<annotation encoding="application / x-tex">X_6< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X7<annotation encoding="application / x-tex">X_7< / annotation>< / semantics>< / com:Math> is H or Y, wherein, optionally, an antibody or antigen- binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00114] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises (a) a VL CDR1 comprising the amino acid sequence SKSL<com:Math><semantics>X11X12<annotation encoding="application / x-tex">X_{11}X_{12}< / annotation>< / semantics>< / com:Math>SNGNTY (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and (c) a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00115] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises (a) a VL CDR1 comprising the amino acid sequence <com:Math><semantics>KSLX19X20SNGNTY<annotation encoding="application / x-tex">KSLX_{19}X_{20}SNGNTY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:118), wherein <com:Math><semantics>X19<annotation encoding="application / x-tex">X_{19}< / annotation>< / semantics>< / com:Math> is V or L, and <com:Math><semantics>X20<annotation encoding="application / x-tex">X_{20}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and (c) a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120), wherein, optionally, an antibody or antigen- binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00116] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00117] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00118] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00119] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00120] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00121] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00122] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00123] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00124] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00125] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00126] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00127] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00128] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00129] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00130] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL, which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00131] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of DIVMTQAAPSX<com:Sub>36< / com:Sub>X<com:Sub>37< / com:Sub>VTPGESVSISCRSSKSLX<com:Sub>38< / com:Sub>X<com:Sub>39< / com:Sub>SNGNTYLYWFLQRPGQSPQRLIYY MSNLASGVPDRFSGRGSGTDFTLX<com:Sub>40< / com:Sub>ISRVEAX<com:Sub>41< / com:Sub>DVGVYYCMQX<com:Sub>42< / com:Sub>LEX<com:Sub>43< / com:Sub>PLTFGGGTKL EIK (SEQ ID NO: 102), wherein <com:Math><semantics>X36<annotation encoding="application / x-tex">X_{36}< / annotation>< / semantics>< / com:Math> is I or V, <com:Math><semantics>X37<annotation encoding="application / x-tex">X_{37}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X38<annotation encoding="application / x-tex">X_{38}< / annotation>< / semantics>< / com:Math> is R or L, <com:Math><semantics>X39<annotation encoding="application / x-tex">X_{39}< / annotation>< / semantics>< / com:Math> is K or H, <com:Math><semantics>X40<annotation encoding="application / x-tex">X_{40}< / annotation>< / semantics>< / com:Math> is R or K, <com:Math><semantics>X41<annotation encoding="application / x-tex">X_{41}< / annotation>< / semantics>< / com:Math> is E or G, <com:Math><semantics>X42<annotation encoding="application / x-tex">X_{42}< / annotation>< / semantics>< / com:Math> is S or G, and <com:Math><semantics>X43<annotation encoding="application / x-tex">X_{43}< / annotation>< / semantics>< / com:Math> is Y or H, wherein, optionally, an antibody or antigen- binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00132] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:2, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00133] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:22, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00134] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:42, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00135] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:62, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00136] In some embodiments, the light chain or antigen-binding portion thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:82, wherein, optionally, an antibody or antigen-binding fragment thereof comprising the antibody light chain or antigen-binding portion thereof (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16.
[00137] In certain embodiments, the antibody light chain or antigen-binding portion thereof comprises a human-derived light chain constant region. In certain embodiments, the light chain constant region has an isotype selected from the group consisting of kappa and lambda. In certain embodiments, the antibody light chain is humanized. In certain embodiments, the antibody light chain is a humanized form of a rodent antibody.
[00138] Also provided herein is an antibody light chain conjugate comprising an antibody light chain provided herein conjugated to an agent. In certain embodiments, the agent is an imaging agent or a cytotoxic agent.
[00139] Also provided herein is a fusion protein comprising an antibody light chain provided herein conjugated via a peptide linker to a scFv. In certain embodiments, the scFv binds CD3.
[00140] Also provided herein is a cell, such as an immune cell, such as a T cell, which recombinantly expresses one or more of the molecules provided herein such as a CAR provided herein.
[00141] Also provided herein is a polynucleotide comprising nucleic acid sequences encoding a scFv provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding a scFv, or conjugate thereof, provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding a CAR provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding an antibody heavy chain, or antigen-binding portion thereof, provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding an antibody heavy chain conjugate provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding an antibody light chain, or antigen-binding portion thereof, provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding an antibody light chain conjugate provided herein. Also provided herein is a polynucleotide comprising nucleic acid sequences encoding the fusion protein provided herein. A polynucleotide comprising nucleic acid sequences encoding (a) an antibody heavy chain, or antigen-binding portion thereof, provided herein or an antibody heavy chain conjugate provided herein; and (b) an antibody light chain, or antigen-binding portion thereof, provided herein, an antibody light chain conjugate provided herein, or a fusion protein provided herein.
[00142] Also provided herein is a vector comprising a polynucleotide provided herein operably linked to a promoter. Also provided herein is a vector comprising (a) a first polynucleotide provided herein operably linked to a first promoter; and (b) a second polynucleotide provided herein operably linked to a second promoter.
[00143] Also provided herein is an ex vivo cell comprising a polynucleotide provided herein operably linked to a promoter. Also provided herein is an ex vivo cell comprising a polynucleotide provided herein operably linked to a promoter. Also provided herein is an ex vivo cell comprising a vector provided herein. Also provided herein is an ex vivo cell comprising one or more polynucleotides encoding an antibody or antigen-binding fragment thereof of provided herein operably linked to a promoter.
[00144] Also provided herein is a method of producing an antibody heavy chain, or antigen- binding portion thereof, comprising culturing a cell provided herein under conditions such that a polynucleotide is expressed by the cell to produce an antibody heavy chain, or antigen-binding portion thereof, or antibody heavy chain conjugate encoded by the polynucleotide.
[00145] Also provided herein is a method of producing an antibody light chain, or antigen- binding portion thereof, comprising culturing a cell provided herein under conditions such that a polynucleotide is expressed by the cell to produce the antibody light chain, or antigen-binding portion thereof, antibody light chain conjugate, or fusion protein encoded by the polynucleotide.
[00146] Also provided herein is a method of producing an antibody or antigen-binding fragment thereof comprising culturing an ex vivo cell provided herein under conditions such that a polynucleotide operably linked to a first promoter and a polynucleotide operably linked to a second promoter are expressed by the cell to produce (i) an antibody heavy chain or an antibody heavy chain conjugate encoded by the polynucleotide; and (ii) an antibody light chain, an antibody light chain conjugate, or a fusion protein encoded by the polynucleotide.
[00147] Also provided herein is a pharmaceutical composition comprising: a therapeutically effective amount of an antibody or antigen-binding fragment thereof provided herein, an antibody conjugate provided herein, a bispecific antibody provided herein, a bispecific antibody conjugate provided herein, a scFv, a scFv conjugate provided herein, a CAR provided herein, an antibody heavy chain, or antigen-binding portion thereof, provided herein, an antibody heavy chain conjugate provided herein, an antibody light chain, or antigen-binding portion thereof, provided herein, an antibody light chain conjugate provided herein, a fusion protein provided herein, or a T cell provided herein; and a pharmaceutically acceptable carrier.
[00148] Also provided herein is a method of treating cancer in a patient in need thereof, comprising administering to said patient the pharmaceutical composition provided herein. In certain embodiments, the cancer is a cancer of the lung, pancreas, breast, uterine, fallopian tube, or primary peritoneum. In certain embodiments, the cancer is a cancer of the ovary. In certain embodiments, the patient is a human patient. In specific embodiments, the method is a combination therapy method, further comprising administering a therapeutically effective amount of an additional therapeutic agent to the patient.
[00149] In a specific embodiment of the combination therapy method, the pharmaceutical composition comprises a therapeutically effective amount of a first antibody that is an antibody or antigen-binding fragment thereof described herein, wherein the antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N-glycosylated Asn1806 of of SEQ ID NO: 150 but does not comprise N-glycosylated Asn1800 of SEQ ID NO: 150, wherein the additional therapeutic agent is a second antibody or antigen-binding fragment thereof, wherein the second antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N-glycosylated Asn1806 of SEQ ID NO: 150 and also comprises N- glycosylated Asn1800 of SEQ ID NO: 150. In a specific embodiment, the first antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind a cell recombinantly expressing a first form of MUC16, which first form of MUC16 is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO: 133; (ii) its lack of immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its ability to immunospecifically bind a cell recombinantly expressing a fourth form of MUC16, which fourth form is glycosylated, and wherein the amino acid sequence of the fourth form is SEQ ID NO: 152, and wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same cell type, and wherein the second antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; and (ii) its lack of immunospecific binding to a cell recombinantly expressing a fifth form of MUC16, which fifth form is glycosylated, and wherein the amino acid sequence of the fifth form is SEQ ID NO:172, wherein the cell recombinantly expressing the first form of MUC16 is the same type of cell as the cell recombinantly expressing the fifth form of MUC16.
[00150] In a specific embodiment of the combination therapy method, the pharmaceutical composition comprises a therapeutically effective amount of a first antibody or antigen-binding fragment thereof that is an antibody or antigen-binding fragment thereof described herein, wherein the antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N-glycosylated Asn1806 of SEQ ID NO: 150 but does not comprise N-glycosylated Asn1800 of SEQ ID NO: 150, wherein the additional therapeutic agent is a therapeutically effective amount of a second antibody or antigen-binding fragment thereof, wherein the second antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N- glycosylated Asn1800 of SEQ ID NO: 150 but does not comprise N-glycosylated Asn1806 of SEQ ID NO: 150. In a specific embodiment, the first antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind a cell recombinantly expressing a first form of MUC16, which first form of MUC16 is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO: 133; (ii) its lack of immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its ability to immunospecifically bind a cell recombinantly expressing a fourth form of MUC16, which fourth form is glycosylated, and wherein the amino acid sequence of the fourth form is SEQ ID NO: 152, wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same cell type, and wherein the second antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) its ability to immunospecifically bind to a cell recombinantly expressing a third form of MUC16, which third form of MUC16 is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its lack of immunospecific binding to a cell recombinantly expressing a fourth form of MUC16, wherein the amino acid sequence of the fourth form is SEQ ID NO:152; and, wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same type of cell.
[00151] Also provided herein is an immunogenic glycopeptide comprising one or more glycosylation sites, wherein (i) the immunogenic glycopeptide is 10 to 60 amino acid residues, 10 to 30 amino acid residues, 15 to 25 amino acid residues, 15 to 20 amino acid residues, or 15 to 18 amino acid residues in length, and (ii) at least one of the one or more glycosylation sites is linked with a carbohydrate. In certain embodiments, the immunogenic glycopeptide comprises one, two, or three glycosylation sites. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site that is linked with a carbohydrate. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites that are each linked with a carbohydrate. In certain embodiments, the carbohydrate is an N- or O-linked carbohydrate. In certain embodiments, the carbohydrate is a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, or a pentasaccharide. In certain embodiments, the carbohydrate is a disaccharide. In certain embodiments, the disaccharide is a chitobiose.
[00152] In certain embodiments, the N-terminus of the immunogenic glycopeptide is acetylated. In certain embodiments, the C-terminus of the glycopeptide is in the form of an N- methylcarboxamide derivative. In certain embodiments, the immunogenic glycopeptide is conjugated to an immunogenic carrier protein. In certain embodiments, the immunogenic carrier protein is keyhole limpet hemocyanin.
[00153] In certain embodiments, the immunogenic glycopeptide is 15 to 18 amino acid residues in length. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site that is linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites that are each linked with a chitobiose.
[00154] In certain embodiments, the immunogenic glycopeptide is 18 amino acid residues in length. In certain embodiments, the immunogenic glycopeptides comprises two glycosylation sites that are each linked with a chitobiose.
[00155] In certain embodiments, the immunogenic glycopeptides is 15 amino acid residues in length. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site that is linked with a chitobiose.
[00156] In certain embodiments, the immunogenic glycopeptide comprises an at least 10 amino acid portion of the amino acid sequence of SEQ ID NO: 150, wherein at least one of the one or more glycosylation sites is in said portion of the amino acid sequence.
[00157] In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO:129.
[00158] In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site at the 30<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:129 that is linked with a chitobiose.
[00159] In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site at the 30<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:129 that is linked with a Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub> moiety.
[00160] In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO: 130. In certain embodiments, the immunogenic glycopeptides comprises two glycosylation sites at the 4<com:Sup>th< / com:Sup> residue (Asn) and the 10<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:130 that are each linked with a chitobiose.
[00161] In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO: 131. In certain embodiments, the immunogenic glycopeptides comprises a glycosylation site at the 7<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO: 131 that is linked with a chitobiose.
[00162] Also provided herein is a method of generating an antibody or an antigen-binding fragment thereof that specifically binds to a glycol-protein, comprising immunizing a subject with an immunogenic glycopeptide comprising one or more glycosylation sites, wherein (i) the immunogenic glycopeptide is 10 to 60 amino acid residues, 10 to 30 amino acid residues, 15 to 25 amino acid residues, 15 to 20 amino acid residues, or 15 to 18 amino acid residues in length, (ii) the immunogenic glycopeptide comprises an at least 10 amino acid portion of the amino acid sequence of the glycoprotein, (iii) at least one of the one or more glycosylation sites is linked with a carbohydrate, and (iv) at least one of the one or more glycosylation sites is in said portion of the amino acid sequence. In certain embodiments, the antibody or antigen-binding fragment thereof lacks specific binding to a non-glycosylated form of the glycoprotein. In certain embodiments, the subject is a goat, a sheep, a donkey, a chicken, a guinea pig, a rat, a rabbit, or a mouse. In certain embodiments, the subject is a rat, a rabbit, or a mouse. In certain embodiments, the subject is a mouse. In certain embodiments, the immunogenic glycopeptide comprises one, two, or three glycosylation sites. The method of any of claims 190-195, wherein the immunogenic glycopeptide comprises a glycosylation site that is linked with a carbohydrate. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites that are each linked with a carbohydrate. In certain embodiments, the carbohydrate is an N- or O- linked carbohydrate. In certain embodiments, the carbohydrate is a monosaccharide, a disaccharide, a trisaccharide, a tetrasaccharide, or a pentasaccharide. In certain embodiments, the carbohydrate is a disaccharide. In certain embodiments, the disaccharide is a chitobiose. In certain embodiments, the N-terminus of the immunogenic glycopeptide is acetylated. In certain embodiments, the C-terminus of the glycopeptide is in the form of an N-methylcarboxamide derivative. In certain embodiments, the immunogenic glycopeptide is conjugated to an immunogenic carrier protein. In certain embodiments, the immunogenic carrier protein is keyhole limpet hemocyanin. In certain embodiments, the immunogenic glycopeptide is 15 to 18 amino acid residues in length. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site that is linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites that are each linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide is 18 amino acid residues in length. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites that are each linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide is 15 amino acid residues in length. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site that is linked with a chitobiose. In certain embodiments, the glycoprotein comprises the amino acid sequence of SEQ ID NO: 150. In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO:129. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site at the 30<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:129 that is linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site at the 30<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:129 that is linked with a Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub> moiety. In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO: 130. In certain embodiments, the immunogenic glycopeptide comprises two glycosylation sites at the 4<com:Sup>th< / com:Sup> residue (Asn) and the 10<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO:130 that are each linked with a chitobiose. In certain embodiments, the immunogenic glycopeptide comprises the amino acid sequence of SEQ ID NO: 131. In certain embodiments, the immunogenic glycopeptide comprises a glycosylation site at the 7<com:Sup>th< / com:Sup> residue (Asn) of SEQ ID NO: 131 that is linked with a chitobiose.
[00163] Also provided herein are antibodies and antigen-binding fragments thereof which immunospecifically bind to MUC16 and which have VH, VL, VH CDR, and / or VL CDR sequences of an antibody described herein (e.g., 10C6, 7B12, 19C11, 16C5, or 18C6), as well as conjugates (e.g., to imaging or cytotoxic agents) thereof. 4. BRIEF DESCRIPTIONS OF FIGURES
[00164] FIG. 1A-FIG. 1I. MUC16 constructs. FIG. 1A: Schematic illustration of MUC16. FIG. 1B: Top: Schematic illustration of MUC16<com:Sup>c344< / com:Sup>. Bottom: Linear representation of the truncated MUC16<com:Sup>c344< / com:Sup> construct. The amino acid sequence of the N-terminus of the first tandem repeat is as set forth in SEQ ID NO: 155. The amino acid sequence of the C-terminus of the first tandem repeat is as set forth in SEQ ID NO: 156. The amino acid sequence of the N-terminus of the ectodomain is as set forth in SEQ ID NO: 157. The amino acid sequence of the C-terminus of the ectodomain is as set forth in SEQ ID NO: 158. FIG. 1C: Top: Schematic illustration of MUC16<com:Sup>c114< / com:Sup>. Bottom: Linear representation of MUC16<com:Sup>c114< / com:Sup>. The amino acid sequence of the ectodomain is as set forth in SEQ ID NO: 161. The amino acid sequence of the transmembrane is as set forth in SEQ ID NO: 159. The amino acid sequence for the cytoplasmic tail is as set forth in SEQ ID NO: 160. FIG. 1D: Top: Schematic illustration of MUC16<com:Sup>c80< / com:Sup>. Bottom: Linear representation of the MUC16<com:Sup>c80< / com:Sup>. The amino acid sequence of the ectodomain is as set forth in SEQ ID NO: 162. The amino acid sequence of the transmembrane is as set forth in SEQ ID NO: 159. The amino acid sequence of the cytoplasmic cail is as set forth in SEQ ID NO: 159. FIG. 1E: Top: Schematic illustration of MUC16<com:Sup>c86< / com:Sup>. Bottom: Linear representation of the MUC16<com:Sup>c86< / com:Sup>. The amino acid sequence of the ectodomain is as set forth in SEQ ID NO: 163. The amino acid sequence of the transmembrane domain is as set forth in SEQ NO: 164. The amino acid sequence of the cytoplasmic domain is SEQ ID NO: 165. FIG. 1F: Linear representation of the <com:Math><semantics>MUC16c114−N123<annotation encoding="application / x-tex">MUC16^{c114-N123}< / annotation>< / semantics>< / com:Math>. The amino acid sequence of <com:Math><semantics>3(N→A)Mutated<annotation encoding="application / x-tex">3(N\rightarrow A)Mutated< / annotation>< / semantics>< / com:Math> Ectodomain 58 aa is as set forth in SEQ ID NO: 166. The amino acid sequence of the transmembrane domain is as set forth in SEQ ID NO: 159. The amino acid sequence of the cytoplasmic domain is as set forth in SEQ ID NO: 160. FIG. 1G, FIG. 1H, and FIG. 1I depict the percent of cells detected by 4H11 via FACS analysis, wherein the cell lines express the indicated MUC16 constructs.
[00165] FIG. 2A-FIG. 2C. In vitro growth curves for MUC16 transfectants. FIG. 2A depicts in vitro growth curves for MUC16<com:Sup>c114< / com:Sup> and MUC16<com:Sup>c344< / com:Sup> cell lines, as compared to the control cell line (phrGFP), in 3T3 cells. FIG. 2B depicts in vitro growth curves for MUC16<com:Sup>c114< / com:Sup> and MUC16<com:Sup>c344< / com:Sup> cell lines, as compared to the control cell line (phrGFP), in A2780 cells. FIG. 2C depicts in vitro growth curves for MUC16<com:Sup>c114< / com:Sup>, MUC16<com:Sup>c80< / com:Sup>, and MUC16<com:Sup>c86< / com:Sup> cell lines, as compared to the control cell line (phrGFP), in 3T3 cells.
[00166] FIG. 3A-FIG. 3E. Effect of MUC16 in 3T3 cells. FIG. 3A depicts soft agar growth of 3T3 transfectants in 60 mm dishes. After 14 days, colonies were counted and plotted. Data shown in the table represent one of three similar experiments (*** <com:Math><semantics>p<0.0001<annotation encoding="application / x-tex">p < 0.0001< / annotation>< / semantics>< / com:Math>) compared to soft agar growth of cells expressing the phrGFP control vector. FIG. 3B depicts matrigel invasion assay for 3T3 cell lines following stable transfections with either phrGFP control vector or with MUC16<com:Sup>c114< / com:Sup> or MUC16<com:Sup>c344< / com:Sup> carboxy-terminus constructs. Each assay was performed two or more times in triplicate and counted by hand. Both MUC16<com:Sup>c114< / com:Sup> and MUC16<com:Sup>c344< / com:Sup> cell lines were significantly more invasive (*** p<0.0001) compared to invasion of cells expressing the phrGFP vector control and the results with the MUC16<com:Sup>c344< / com:Sup> cell line was significantly different from the results with the <com:Math><semantics>MUC16c114<annotation encoding="application / x-tex">MUC16^{c114}< / annotation>< / semantics>< / com:Math> cell line ((# p=0.0354). FIG. 3C depicts the expression of metastasis and invasion genes induced by MUC16<com:Sup>c114< / com:Sup> and MUC16<com:Sup>c344< / com:Sup> expression. A SuperArray panel of 80 invasion / metastasis gene transcripts was examined for MUC16-construct-positive and vector only cell lines. The expression of selected chemotactic, adhesion, and invasion transcripts was measured in 3T3 MUC16<com:Sup>c114< / com:Sup> or 3T3-MUC16<com:Sup>c344< / com:Sup> cell lines (each of three triplicates was examined in duplicate and compared to the phr vector only controls by chi square testing). The p value for each transcript, adjusted for repeated measures, is shown in the table. All genes with changes at the p<0.05 or below level are included. FIG. 3D: Transfected 3T3 cells were examined for activation of the ERK / AKT signaling pathways compared to the vector only controls. Phosphorylation of ERK1 / 2 (pT202 / Y204) and AKT (S473) was increased following expression of the MUC16<com:Sup>c114< / com:Sup> and MUC16<com:Sup>c344< / com:Sup> constructs, as compared to the expression of the phr vector. Activation of both pathways was seen in each of the cell lines. B-actin normalized densitometry quantification values are shown below each western blot in the figure. FIG. 3E depicts MUC16-construct-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 15 nu / nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16-construct-positive tumors (both lines p<0.0001 compared to cells expressing the phrGFP control vector).
[00167] FIG. 4A-FIG. 4C. Oncogenic properties of MUC16 fragments. FIG. 4A depicts matrigel invasion assay for A2780 cell lines transfected either phrGFP control vector or with MUC16 carboxy-terminus expression vectors, MUC16<com:Sup>c114< / com:Sup> or MUC16<com:Sup>c344< / com:Sup>. Each assay was performed two or more times in triplicate and counted by hand. Results were compared to matrigel invasion of cells expressing phrGFP control vector or MUC16<com:Sup>c114< / com:Sup>. MUC16<com:Sup>c114< / com:Sup> or MUC16<com:Sup>c34< / com:Sup> cell lines showed significant matrigel invasion relative to phrGFP vector control, and the results with the MUC16<com:Sup>c344< / com:Sup> cell line was significantly different from the results with the MUC16<com:Sup>c114< / com:Sup> cell line (##p=0.0018). FIG. 4B depicts the effect of MUC16 expression on ERK / AKT signaling. A2780 cells were examined for activation of the ERK / AKT signaling pathways. Phosphorylation of ERK1 / 2 (pT202 / Y204) and AKT (S473) was increased following expression of each of the MUC16 expression constructs. Both pathways were activated in each of the cell lines. β-actin normalized densitometry quantification values are shown below each western blot in the figure. FIG. 4C depicts MUC16-construct-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 15 nu / nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing any of the MUC16<com:Sup>c114< / com:Sup>- or MUC16<com:Sup>c344< / com:Sup>-positive tumors at day 28, as indicated in the figure.
[00168] FIG. 5A-FIG. 5D: Effects of truncated MUC16<com:Sup>c114< / com:Sup> variants. FIG. 5A: Soft agar growth. 3T3 transfectants expressing either internal or external domain portions of MUC16<com:Sup>c114< / com:Sup> were layered on soft agar, as described in Section 6.1.2. Colonies were counted and plotted. The data shown represent one of three experiments. Soft agar growth rates for MUC16<com:Sup>c80< / com:Sup> and <com:Math><semantics>MUC16c86<annotation encoding="application / x-tex">MUC16^{c86}< / annotation>< / semantics>< / com:Math> were significantly different compared to the growth rate for <com:Math><semantics>MUC16c114<annotation encoding="application / x-tex">MUC16^{c114}< / annotation>< / semantics>< / com:Math> (# p =0.0111 and ## p=0.0258, respectively), whereas a higher level of significance was seen with the growth rate for MUC16<com:Sup>80< / com:Sup> transfectant compared to the growth rate for MUC16<com:Sup>c86< / com:Sup> transfectant (### p<0.0001). FIG. 5B depicts matrigel invasion assay for 3T3 cell lines transfected either phrGFP control vector or with MUC16 carboxy-terminus constructs. Each assay was performed two or more times in triplicate and counted by hand. Invasion of the MUC16<com:Sup>c80< / com:Sup> transfectant cells was significant (# p=0.0172) as compared to invasion of the MUC16<com:Sup>c114< / com:Sup> cell line. FIG. 5C depicts the effect of MUC16 expression on ERK / AKT signaling. Transfected 3T3 cells were examined for activation of the ERK / AKT signaling pathways. Phosphorylation of ERK1 / 2 (pT202 / Y204) and AKT (S473) was increased following MUC16<com:Sup>c114< / com:Sup>; however, the signals were lower in cells transfected with MUC16<com:Sup>c80< / com:Sup> or MUC16<com:Sup>c86< / com:Sup> constructs. β-Actin normalized densitometry quantification values are shown below each western blot in the figure. FIG. 5D depicts MUC16-construct-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 20 nu / nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16+ tumors. 3T3 MUC16<com:Sup>c114< / com:Sup> and 3T3 MUC16<com:Sup>c86< / com:Sup> transfectants were significantly different compared to MUC16<com:Sup>c80< / com:Sup> transfectants (### p<0.0001).
[00169] FIG. 6A- FIG. 6B. Amino acid sequence for MUC16<com:Sup>c114< / com:Sup> (amino acid residues 1777 to 1890 (SEQ ID NO: 133), FIG. 6A) and MUC16<com:Sup>c344< / com:Sup> (amino acid residues 1547 to 1890 (SEQ ID NO: 132), FIG. 6B). The N- and O-glycosylation sites are highlighted and the transmembrane domain (amino acid residues 1835 to 1859) is underlined and labeled "Transmembrane Domain." Amino acid residues 1857-1884 represent the 28 amino acid internal domain deletion present in the MUC16<com:Sup>c86< / com:Sup> construct (see, FIG. 1). Amino acid residues 1798-1831 represent the 34 amino acid ectodomain deletion present in the MUC16<com:Sup>c80< / com:Sup> construct (see, FIG. 1).
[00170] FIG. 7A - FIG. 7H. Effect of N-Glycosylation on MUC16 transformation. FIG. 7A depicts matrigel invasion assay for 3T3 cell lines transfected with phrGFP control vector or MUC16<com:Sup>c114< / com:Sup> or MUC16<com:Sup>c114-N123< / com:Sup> and MUC16<com:Sup>c114< / com:Sup> treated with 0.1 µg / mL Tunicamycin. Results with the MUC16<com:Sup>c114< / com:Sup> cell line was significantly different (### p<0.0001) than results with the phrGFP vector control cell line. Results with the MUC16<com:Sup>c114-N123< / com:Sup> cell line were significantly different (** p=0.007) compared to results with the phrGFP vector control cell line. Treatment with the N-glycosylation inhibitor Tunicamycin significantly inhibited matrigel invasion compared to the untreated MUC16<com:Sup>c114< / com:Sup> (p=0.004). FIG. 7B depicts matrigel invasion assay for 3T3 transfected cell lines compared to phrGFP control vector. 3T3 cells transfected with MUC16<com:Sup>c114< / com:Sup> were treated with media alone, or treated with 5 μg / mL of control pFUSE hIgG1-Fc2 fusion protein, or with 5 µg / mL of MUC16<com:Sup>c57-c114< / com:Sup>-pFUSE hIgG1-Fc2 fusion protein or with 5 μg / mL of <com:Sup>117-244< / com:Sup>LGALS3-pFUSE hIgG1-Fc2 fusion protein as detailed in FIG. 8. The MUC16<com:Sup>c114< / com:Sup> cell line was much more invasive than the control 3T3 cells (*** p<0.0001) expressing phrGFP vector control and this was unaffected by exposure to pFUSE vector only protein. In contrast, the MUC16<com:Sup>c114< / com:Sup> cell line treated with MUC16<com:Sup>c57-c114< / com:Sup>-pFUSE hIgG1-Fc2 fusion protein or <com:Sup>117-244< / com:Sup>LGALS3-pFUSE hIgG1-Fc2 fusion protein demonstrated significant inhibition of matrigel invasion compared to MUC16<com:Sup>c114< / com:Sup> control cells. FIG. 7C depicts the effect of MUC16 expression on ERK / AKT signaling. Transfected 3T3 cells were also examined for activation of the ERK / AKT signaling pathways. Phosphorylation of ERK1 / 2 (pT202 / Y204) and AKT (S473) was increased in the 3T3 transfected with MUC16<com:Sup>c114< / com:Sup>; however, the effect was diminished in 3T3 cells transfected with the MUC16<com:Sup>c114-N123< / com:Sup> vector ("MUC16<com:Sup>c114-N123< / com:Sup>" and "MUC16<com:Sup>3(N-->A)c114< / com:Sup>" are used herein interchangeably). Despite mutations the 3 asparagine to alanine mutations, western blot with an anti-MUC16 antibody (4H11 mAb) showed a higher signal than either the phrGFP vector control or the native MUC16<com:Sup>c114< / com:Sup>-transfected cells, indicating that the high levels of MUC16<com:Sup>3(N-->A)c114< / com:Sup> protein is expressed in the transfected 3T3 cells. As used herein, "4H11" refers to the monoclonal anti-MUC16 antibody designated as 4H11 in Rao et al. Appl. Immunohistochem Mol Morphol, 2010, 18(5):462-72 and in International Patent Application Publication No. WO 2011 / 119979. FIG. 7D depicts MUC16-construct-positive tumor growth in athymic nude mice. Two million tumor cells were introduced into the flank of 20 nu / nu mice, and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were significantly greater for mice bearing MUC16<com:Sup>c114< / com:Sup> tumors (p<0.0001). Results with the 3T3-MUC16<com:Sup>c114< / com:Sup> transfectant were highly significant as compared to results with the phrGFP control vector cell line (*** p<0.0001). However, MUC16<com:Sup>c114-N123< / com:Sup> 3T3 transfectants did not show any significance over phrGFP vector control 3T3 cells indicating that the mutations of N-glycosylation dramatically decreased tumor growth and invasion. FIG. 7E depicts the linear representation of the MUC16<com:Sup>c57-114< / com:Sup>-pFUSE-human-IgG1-Fc2 construct. The amino acid sequence of the ectodomain is as set forth in SEQ ID NO: 161. FIG. 7F depicts protein levels of MUC16<com:Sup>c57-114< / com:Sup>-pFUSE- human-IgG1-Fc2 construct determined by the indicated antibodies. FIG. 7G depicts the linear representation of the <com:Sup>117-244< / com:Sup>LGALS3-pFUSE-human-IgG1-Fc2 construct. The amino acid sequence of the sugar binding domain is as set forth in SEQ ID NO: 167. FIG. 7H depicts protein levels of <com:Sup>17-244< / com:Sup>LGALS3-pFUSE-human-IgG1-Fc2 construct determined by the indicated antibodies.
[00171] FIG. 8. Sequence for the ectodomain-MUC16<com:Sup>c57->c114< / com:Sup> (SEQ ID NO: 161; amino acid residues 1777-1834 of MUC16) amino acid sequence inserted into the pFUSE-hIgG1-Fc2 vector to construct the MUC16<com:Sup>c57-c114< / com:Sup>pFUSE as a sham receptor and the <com:Sup>117-244< / com:Sup>LGALS3 amino acid sequence (SEQ ID NO: 167) inserted into pFUSE-hIgG1-Fc2, resulting in the <com:Sup>117< / com:Sup>- <com:Sup>244< / com:Sup>LGALS3pFUSE vector.
[00172] FIG. 9A - FIG. 9E. MUC16c354 transgenic mice. FIG. 9A depicts the strategy for the MUC16<com:Sup>c354< / com:Sup> conditional construct. A CMV early enhancer plus the chicken β actin promoter (CAG) was used to drive the transcription of hrGFP between two loxPs and the downstream MUC16<com:Sup>c354< / com:Sup> sequence. FIG. 9B: Southern blot shows 12 candidates of MUC16<com:Sup>c354< / com:Sup> positive founders among 99 animals after microinjection procedure. FIG. 9C: Western blot with anti- MUC16 antibody, 4H11, was used to identify founders 9 (~50 copies) and 36 (~10 copies) for MUC16<com:Sup>c354< / com:Sup> mouse colony development; A5 is a positive control from a stable transfected SKOV3 with MUC16<com:Sup>c354< / com:Sup>. FIG. 9D: Histological analyses of tumors from double MUC16<com:Sup>c354< / com:Sup>:p53+ / -transgenic mice. Multiple sarcomas and lymphomas were identified in the double MUC16<com:Sup>c354< / com:Sup>:p53+ / - transgenic mice. Sections were stained with hematoxylin and eosin (H&E). Tumor include histocytic sarcoma in uterus (I, Scale bar: 100μm), liver (II, Scale bar:50μm), ovary (III, Scale bar:50μm) and bone marrow (IV, Scale bar:50μm) as well as lymphoma in ovary (V, Scale bar:50µm), kidney (VI, Scale bar:50µm), and lung (VII, Scale bar:50µm) with carcinoma in the lung (VIII, Scale bar:50µm). FIG. 9E: Transgenic mouse cancer specific Kaplan-Meier Survival Curves: the MUC16<com:Sup>c354< / com:Sup> mice showed no spontaneous tumor development over the first 18 months, similar to the wild type (WT). However, when MUC16<com:Sup>c354< / com:Sup> mice were crossed with p53+ / - mice, the double transgenic MUC16<com:Sup>c354< / com:Sup>:p53+ / - mice showed a significantly worse overall survival due to spontaneous tumor development compared to either the p53+ / - mice (p<0.014) or the MUC16<com:Sup>c354< / com:Sup> mice.
[00173] FIG. 10. Representative tissue histological from 12 months old male and female MUC16<com:Sup>c354< / com:Sup> transgenic mice. Tissue sections were stained with hematoxylin and eosin (H&E, Scale bar: 50µm). Uterine endometrial hyperplasia was observed with similar incidence and severity in both genotypes (here only shown in the transgenic animal). The ovary, lung, colon and liver of transgenic animals (Tg) were similar to the parental line (wild type, WT).
[00174] FIG. 11A- FIG. 11C. Impact of MUC16 in human ovarian cancer. FIG. 11A depicts MUC16 transcript numbers. FIG. 11B: The quintile of patients with the highest MUC16 expression, combined with the 18 patients with identified MUC16 mutations, have a significantly (p=0.02117) worse survival when compared to the patients with lower MUC16 expression in a Kaplan-Meier analysis. FIG. 11C depicts the relationship of MUC16 genetic alterations with PI3K mutational events in ovarian cancer.
[00175] FIG. 12A- FIG. 12C. Glycosylation requirements for MUC16 matrigel invasion. FIG. 12A depicts matrigel invasion assay for SKOV3 transfected cell lines. phrGFP refers to SKOV3 cells expressing a control vector. MUC16<com:Sup>c114< / com:Sup> refers to SKOV3 cells expressing MUC16<com:Sup>c114< / com:Sup>. N3 refers to SKOV3 cells expressing MUC16<com:Sup>c114-N3< / com:Sup>. N1-2 refers to SKOV3 cells expressing MUC16<com:Sup>c114-N12< / com:Sup>. N1-2-3 refers to SKOV3 cells expressing MUC16<com:Sup>c114-N123< / com:Sup>. MUC16<com:Sup>c114< / com:Sup>-shControl refers to SKOV-3 cells expressing MUC16<com:Sup>c114< / com:Sup> and a control shRNA. phrGFP shRNA MGAT population #4 refers to SKOV3 cells expressing a control vector and shRNA against MGAT5. phrGFP shRNA LGALS3 population #15 refers to SKOV3 cells expressing a control vector and shRNA against LGALS3. MUC16<com:Sup>c114< / com:Sup>-shMGAT5 refers to SKOV3 cells expressing MUC16<com:Sup>c114< / com:Sup> and an shRNA against MGAT5. MUC16<com:Sup>c114< / com:Sup>-shLGALS3 refers to SKOV3 cells expressing MUC16<com:Sup>c114< / com:Sup> and an shRNA against LGALS3. FIG. 12B depicts matrigel invasion assay for 3T3 cells expressing the control vector, phrGFP, or the indicated MUC16<com:Sup>c114< / com:Sup> constructs. FIG. 12C depicts the tumor growth, as determined by tumor volume, in athymic nude mice implanted with SKOV3 cells expressing the indicated constructs.
[00176] FIG. 13A- FIG. 13D. MUC16 glycosylation patterns and peptides. FIG. 13A depicts the N-linked profiling of SKOV3 cells expressing MUC16<com:Sup>c114-N12< / com:Sup>. Triangles represent fucose. Squares represent N-acetylglucosamine. Grey circles represent mannose. White circles represent galactose. Diamonds represent N-acethylneuramic acid. FIG. 13B depicts the 55-mer (SEQ ID NO:129) immunogen. FIG. 13C depicts the 15-mer (SEQ ID NO:131) immunogen. FIG. 13D depicts the 18-mer (SEQ ID NO:130) immunogen.
[00177] FIG. 14 provides a detailed ELISA analysis of the relative reactivity of bioreactive supernatants comprising MUC16 Glycosylation Antibodies with glycosylated and unglycosylated antigens for both the 15 mer and the 18 mer used as immunogens and screening antigen targets.
[00178] FIG. 15A- FIG. 15B. MUC16 Glycosylation Antibodies inhibit matrigel invasion. FIG. 15A depicts matrigel invasion of SKOV3 cells expressing phrGFP control vector or MUC16<com:Sup>c114< / com:Sup> in the presence or absence of bioreactive supernatants from the generation of MUC16 Glycosylation Antibodies. The line is a reference line for the relative number of 200. FIG. 15B depicts matrigel invasion of SKOV3 cells expressing phrGFP control vector or MUC16<com:Sup>c114< / com:Sup> in the presence or absence of purified MUC16 Glycosylation Antibodies. The line is a reference line for the relative number of 90.
[00179] FIG. 16A- FIG. 16E. MUC16 Glycosylation Antibodies inhibit matrigel invasion. FIG. 16A depicts matrigel invasion of SKOV3 cells expressing phrGFP control vector or the indicated MUC16<com:Sup>c114< / com:Sup> constructs in the presence of (i) control antibody; (ii) 4H11; or (iii) MUC16 Glycosylation Antibody clone 10C6.E4. FIG. 16B depicts matrigel invasion of SKOV3 cells stably expressing phrGFP control vector or the indicated MUC16<com:Sup>c344< / com:Sup> constructs after a third FACs sort using 4H11, in the presence of (i) control antibody; (ii) 4H11; or (iii) MUC16 Glycosylation Antibody clone 10C6.E4. FIG. 16C depicts matrigel invasion of 3T3 cells expressing phrGFP control vector or the indicated MUC16<com:Sup>c114< / com:Sup> constructs in the presence of (i) control antibody; (ii) 4H11; or (iii) MUC16 Glycosylation Antibody clone 10C6.E4. FIG. 16D depicts the tumor growth, as indicated by tumor volume, in athymic nude mice implanted with SKOV3 cells expressing MUC16<com:Sup>c344< / com:Sup> and mock treated (MUC16<com:Sup>c344< / com:Sup>) or treated with the MUC16 Glycosylation Antibody 10C6.E4(MUC16<com:Sup>c344< / com:Sup> +10C6.E4). Arrows indicate days on which 100 μg of the MUC16 Glycosylation Antibody was administered. FIG. 16E depicts staining of human ovarian tumor samples with the indicated antibodies.
[00180] FIG. 17 depicts the percent of cells in which the labeled MUC16 Glycosylation Antibody is internalized at the indicated temperature and timepoints.
[00181] FIG. 18A depicts in vitro growth curves for MUC16 transfectants. 1000 SKOV3 cells / well in 96 well flat-bottomed plates were cultured with phrGFP vector control, phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133), or phrGFP vector expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132) and incubated at 37 °C in 5% CO<com:Sub>2< / com:Sub> for 5 days. Each day, a plate was stained with Alamar Blue and incubated at 37 °C in 5% CO<com:Sub>2< / com:Sub> for 4 hours. Plates were read in a CytoFluor Fluorescent plate reader. No statistical differences were seen among the curves. FIG. 18B depicts matrigel invasion assay for SKOV3 phrGFP cells, SKOV3 MUC16<com:Sup>c114< / com:Sup>-GFP cells, or SKOV3-MUC16<com:Sup>c344< / com:Sup>-GFP cells. Each assay was performed two or more times in triplicate and counted by hand. Results are expressed as the relative number of invasive cells. c114 and c344 were statistically significant as compared with phrGFP. FIG. 18C depicts SKOV3 transfectant tumor growth in athymic female nude mice. Two million tumor cells were introduced into the flank of 10 nu / nu mice and the mice were observed for tumor formation. Tumors were measured by calipers twice weekly. The differences in mean tumor volume were statistically significantly greater for mice bearing MUC16<com:Sup>c344< / com:Sup> tumors (p<0.0001) and MUC16<com:Sup>c114< / com:Sup> tumors (p=0.002) when compared to phrGFP tumors. Abbreviations for FIG. 18A-FIG.18C: "SKOV3 phrGFP" and "phrGFP" refer to SKOV3 cells expressing control phrGFP vector; "SKOV3 MUC16<com:Sup>c114< / com:Sup>-GFP" and "c114" refer to SKOV3 cells expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133); "SKOV3 MUC16<com:Sup>c344< / com:Sup>-GFP" and "c344" refer to SKOV3 cells expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132).
[00182] FIG. 19A- FIG. 19F depict the effect of MUC16 Expression on SKOV3 ovarian cancer cells. FIG. 19A depicts a matrigel invasion assay for SKOV3 cells expressing control phrGFP control vector ("phrGFP") or the phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133; "c114") treated with or without the following: (1) 5 μg / mL tunicamycin; (2) 5 μg / mL of control pFUSE protein; (3) 5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>g / mL of MUC16<com:Sup>e57-114< / com:Sup>-pFUSE fusion protein; or (4) 5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>g / mL of <com:Sup>117-244< / com:Sup>LGALS3-pFUSE fusion protein. The results are expressed as number of invasive cells 48 hours-post-treatment. c114 cells were more invasive than phrGFP cells (p<0.0001). The invasive properties of the c114 cells were not affected by treatment with the pFUSE vector-only protein. Treatment with tunicamycin (an N-glycosylation inhibitor) decreased the invasive properties of the c114 cells. Treatment with MUC16<com:Sup>c57-114< / com:Sup>-pFUSE fusion protein or <com:Sup>117< / com:Sup>- <com:Sup>244< / com:Sup>LGALS3-pFUSE decreased the invasive properties of the c114 cells (p<0.0001). FIG. 19B depicts a matrigel invasion assay for SKOV3 cells transfected with phrGFP vector control ("phrGFP") or phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133) ("c114") in the presence or absence of lamelli control shRNA, MGAT5-specific shRNA, or LGALS3-specific shRNA. c114 cells treated with MGAT5-specific shRNA or LGALS3-specific shRNA had decreased invasion as compared to phrGFP cells treated with the shRNAs. The control shRNA has no impact on c114 cell invasion. Each assay was performed two or more times in triplicate and counted by hand. FIG. 19C depicts the glycosylation dependence of SKOV3-MUC16<com:Sup>c114< / com:Sup> matrigel invasion. SKOV3 cells were transfected with phrGFP control vector or phrGFP vector expressing the following MUC16 mutants: c114 (SEQ ID NO: 133), N1 mut c114 (SEQ ID NO: 151), N24 muc c114 (SEQ ID NO: 152), N30 mut c114 (SEQ ID NO:139), N1-N24 mut c114 (SEQ ID NO: 153), N1-N24-N30 mut c114 (SEQ ID NO: 154). The c114-expressing cells displayed increased invasion when compared to the control phrGFP cells. The increased invasive property of the c114-expressing cells was dependent on N-glycosylation of the asparagines at amino acid positions 24 and 30 of MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133). While both N24 and N30 sites were important, the N30 position appeared to be more crucial than the N24 site for this effect. Each assay was performed two or more times in triplicate and counted by hand. Results are expressed as % compared to phrGFP vector control. FIG. 19D depicts the glycosylation dependence of SKOV3-MUC16<com:Sup>c344< / com:Sup> matrigel invasion. SKOV3 cells were transfected with phrGFP control vector or phrGFP vector expressing the following MUC16 mutants: c344 (SEQ ID NO: 132), N24 mut c344 (SEQ ID NO: 173), N30 mut c344 (SEQ ID NO: 174), or N24-N30 mut c344 (SEQ ID NO: 175). The c344-expressing cells displayed increased invasion when compared to the control phrGFP cells. The increased invasive property of the c344-expressing cells was dependent on N-glycosylation of the asparagines corresponding to amino acid positions 24 and 30 of MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133). Each assay was performed two or more times in triplicate and counted by hand. FIG. 19E depicts the effect of MUC16- expression on selected signaling pathways. SKOV3 cells transfected with MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133) were treated with or without control shRNA ("shLamelli") or shRNA against MGAT5 ("shMGAT5") or LGALS3 ("shLGALLS3") and compared to SKOV3 cells transfected phrGFP vector control ("phrGFP") or phrGFP vector expressing MUC16<com:Sup>c114-N30mut< / com:Sup> (SEQ ID NO: 139) ("N30 mut") and the cells were examined for activation of the pAKT, pERK1 / 2, pSRC, and pEGF receptor (pEGFR) signaling pathways. Phosphorylation of AKT (S473) and ERK1 / 2 (pT202 / Y204) were increased in the MUC16<com:Sup>c114< / com:Sup> cells. Knockdown of MGAT5 (shMGAT5), knockdown of Galectin-3 (shLGALLS3), and the N30A mutation each reduced MUC16<com:Sup>c114< / com:Sup>- induced oncogene activation in the SKOV3 cell lines. FIG. 19F depicts SKOV3 transfectant tumor growth in athymic female nude mice. Two million tumor (described below) cells were introduced into the flank of 10 nu / nu mice for each condition, and mice were observed for tumor formation. Tumors were measured by calipers twice per week. In vivo growth of c114 tumor cells was much more aggressive (p<0.0001) as compared to phrGFP tumor cells. N1-N24-N30- mut c114, c114-sh-MGAT5, and c114-sh-LGALS3 tumor cells did not display growth enhancement when compared to phrGFP tomuor cells. Description of tumor cells: "phrGFP" refers to SKOV3 cells transfected with phrGFP vector control; "c114" refers to SKOV3 cells transfected with phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133); "N1-N24-N30-mut c114" refers to SKOV3 cells transfected with phrGFP vector expressing MUC16<com:Sup>c114-N1-N24-N30-mut< / com:Sup> (SEQ ID NO: 154); "c114-sh-MGAT5" refers to SKOV3 cells transfected with phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133) and treated with shRNA against MGAT5; and "c114- sh-LGALS3" refers to SKOV3 cells transfected with phrGFP vector expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133) and treated with shRNA against LGALS3.
[00183] FIG. 20A depicts the effect of MUC16 expression on EGFR surface expression. SKOV3-phrGFP and SKOV3-MUC16<com:Sup>c114< / com:Sup> transfectants were examined in the presence or absence of treatingment with cycloheximide (CHX) for 24 hours. Geometric mean fluorescence of EGFR and MUC16 expression at basal and post-CHX treated levels is shown. EGFR in SKOV3-phrGFP samples was reduced to 58% of untreated levels after 24 hours of treatment with CHX. No significant MUC16 expression was present in these cells. In contrast, in the SKOV3-MUC16<com:Sup>c114< / com:Sup> cells, there was roughly a 25% increase in EGFR geometric mean fluorescence, which decreased to 83% of that of the control after CHX exposure. MUC16<com:Sup>c114< / com:Sup> mean fluorescence was not significantly reduced by CHX. FIG. 20B depicts densitometry of the EGFR / β-actin ratio from western blots of total cellular EGFR and illustrates that there was a steady loss of EGFR over time in SKOV3-phrGFP cells treated with CHX. In contrast, the total level of EGFR in SKOV3-MUC16<com:Sup>c114< / com:Sup> cells was maintained, showing EGFR stabilization compared with the MUC16(-) control cell line ("phrGFP (-)"). FIG. 20C depicts a matrigel invasion assay for SKOV3 cells transfected with phrGFP control vector ("stable phrGFP"), SKOV3-MUC16<com:Sup>c114< / com:Sup> and SKOV3-MUC16<com:Sup>c114(tet)< / com:Sup> tetracycline-inducible cell lines, expressed as a fraction of control cell invasion. Tetracycline induction of SKOV3-MUC16<com:Sup>c114(tet)< / com:Sup> cells resulted in an invasive phenotype similar to the stable SKOV3-MUC16<com:Sup>c114< / com:Sup> (SKOV3<com:Sup>c114< / com:Sup>), while un- induced cells matched the MUC16-phrGFP control cells. This MUC16-induced increase in matrigel invasion was completely dependent on EGFR. When a hairpin RNA knockdown of EGFR (shEGFR) was introduced into SKOV3 cells, tetracycline induced expression of MUC16 (4H11 positive protein in western blot) but did not increase matrigel invasion. Each assay was performed in triplicate and counted by hand. FIG. 20D: EGFR stability in MUC16<com:Sup>c114< / com:Sup>(+) and MUC16<com:Sup>c114< / com:Sup>(-) cells. Cell extracts of un-induced or tetracycline-induced SKOV3- MUC16c114(tet) cell lines treated with CHX for 24 hours and probed for total cellular EGFR are expressed as densitometry ratios, and normalized with β-Actin. The slope of the EGFR decline in tetracycline-induced SKOV3-MUC16<com:Sup>c114< / com:Sup> cells replicates the EGFR stabilization effect of MUC16<com:Sup>c114< / com:Sup> expression compared with the MUC16<com:Sup>c114< / com:Sup>(–) line. The result is similar to the effect of stable transfection shown above in FIG. 20B).
[00184] FIG. 21 depicts densitometry for western blot analysis of cell extracts of un-induced or tetracycline-induced SKOV3<com:Sup>c114< / com:Sup> cell lines ("Uninduced MUC16<com:Sup>c114< / com:Sup>" and "Tet-induced MUC16<com:Sup>c114< / com:Sup>", respectively) treated with cycloheximide for 24 hours. The western blots were probed for pEGFR and protein levels were normalized to β-Actin levels. The slopes of the tetracycline-induced SKOV3<com:Sup>c114< / com:Sup> pEGFR signal showed stabilized pEGFR compared with un- induced SKOV3<com:Sup>c114< / com:Sup> cell line.
[00185] FIG. 22A- FIG. 22C depict the identification and chemical synthesis of MUC16 ectodomain N-glycosylated species. FIG. 22A: N-glycan profiling of SKOV3 cells transfected with phrGFP expressing N1-N24 mutated MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: SEQ ID NO: 153). The glycans were detected and characterized by total ion mapping at the Complex Carbohydrate Research Center, University of Georgia. Triangles: fucose; squares: N-acetylglucosamin; circles, dark fill: mannose; circles, light fill: galactose; diamonds: N-acetylneuraminic acid. FIG. 22B depicts the schematic structure of a 55-mer MUC16 antigen with a single chitobiose (GlcNAc<com:Sub>2< / com:Sub>) glycan at the N30 position. This N-glycopeptide antigen was used to immunize mice to raise antibodies. The amino acid sequence is as set forth in SEQ ID NO: 129. Squares represent N- acetylglucosamin; circles represent mannose. FIG. 22C depicts the schematic structure of a KLH-conjugated, 15-mer MUC16 antigen mono-glycosylated with chitobiose at the N30 position, and KLH-conjugated, 18-mer MUC16 antigen bis-glycosylated with two chitobiose units at the N24 and N30 positions, respectively. These N-glycopeptide-KLH constructs were subsequently used to immunize mice to raise monoclonal antibodies against the GlcNAc<com:Sub>2< / com:Sub>- peptide epitope within the MUC16 ectodomain. Sequences of the MUC16-unrelated glycopeptides and the nonglycosylated MUC16 peptide 2 to elicit the 4H11 monoclonal antibody are included as well. The amino acid sequence for KLH-15-mer(chitobiose)[C-G25-V38] is as set forth in SEQ ID NO: 131. The amino acid sequence for KLH-18-mer(chitobiose)<com:Sub>2< / com:Sub>[C-T22- V38] is as set forth in SEQ ID NO: 130. The amino acid sequence for MUC16 Nonglycosylated Peptide2 is as set forth in SEQ ID NO: 168. The amino acid sequence for MUC16 unrelated peptide 18mer and MUC16 unrelated peptide 18mer + GlcNAc2 is as set forth in SEQ ID NO: 169. Squares represent N-acetylglucosamin.
[00186] FIG. 23A-FIG. 23H depict MUC16 Glycosylation Antibody characterization. FIG. 23A depicts the reactivity of 4H11 and four lead GlcNAc<com:Sub>2< / com:Sub>-MUC16-ectodomain monoclonal antibodies (MUC16 Glycosylation Antibodies) to various MUC16 and GlcNAc<com:Sub>2< / com:Sub>-glycosylated peptides by sandwich ELISA. No glycan-MUC16 ectodomain cross reactivity was seen with the nonglycosylated MUC16 peptide 2 (SEQ ID NO: 168), or either of the unrelated peptides (SEQ ID NO: 169). Similarly, 4H11 had essentially no affinity for the GlcNAc<com:Sub>2< / com:Sub>-MUC16 15-mer (SEQ ID NO: 131) or (GlcNAc<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-18-mer (SEQ ID NO: 130) N-glycopeptides. Squares represent N- acetylglusoamin; triangles represent fucose; circles represent mannose. FIG. 23B, FIG. 23C, and FIG. 23D depict the effect of MUC16 Glycosylation Antibodies on MUC16-enhanced matrigel invasion. Results are expressed as % compared to control. Matrigel assay of SKOV3 cells transfected with phrGFP expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133) (FIG. 23B), CAOV3 cells (FIG. 23C) and OVCA-433 cells (FIG. 23D) with or without (control) purified 4H11 or the four glycan-MUC16-ectodomain antibodies 18C6, 10C6, 19C22, or 7B12 at 5 μg / mL. Each of the four anti-glycan-MUC16-ectodomain antibodies (MUC16 Glycosylation Antibodies) inhibited the invasion of three different MUC16(+) ovarian cancer cell lines (CAOV3 and OVCA-433), while 4H11 had less effect on inhibiting invasion of the SKOV3-MUC16<com:Sup>c114< / com:Sup> cells. FIG. 23E depicts the inhibition of EGFR stabilization by MUC16 Glycosylation Antibody monoclonal antibody ("MAB") 10C6. The densitometry of western blot analysis from cell extracts of un-induced SKOV3-MUC16<com:Sup>c114(tet)< / com:Sup>, tetracycline-induced SKOV3-MUC16<com:Sup>c114(tet)< / com:Sup>, or monoclonal MUC16 Glycosylation Antibody 10C6-treated, tetracycline-induced SKOV3- MUC16<com:Sup>c114(tet)< / com:Sup> cell lines treated with CHX and then probed for total EGFR at the indicated hours (hrs) post-treatement with cyclohexamind. As seen in FIG. 20A, the slopes of the densitometry curves indicated that the presence of MUC16<com:Sup>c114< / com:Sup> on the cell surface stabilized EGFR. The MUC16 Glycosylation Antibody 10C6 abrogated the MUC16<com:Sup>c114< / com:Sup> stabilization of total EGFR protein, making it similar to the MUC16(–) un-induced control. FIG. 23F depicts human ovarian tissue microarrays stained with 4H11, OC125 (commercial), or monoclonal MUC16 Glycosylation Antibodies (10C6 and 19C11). The expression of MUC16 on the serous ovarian cancer was consistent and overlapped with OC125 and 4H11. FIG. 23G and FIG. 23H depict the effect of MUC16 Glycosylation Antibodies on tumor growth in athymic female nude mice. Two million tumor cells (SKOV3 cells transfected with phrGFP vector ("phrGFP") or phrGFP vector expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132; "c344")) were introduced into the flank of 20 nu / nu mice. Ten mice were treated intravenously from day 0 with purified monoclonal MUC16 Glycosylation Antibody 10C6 at 100 µg / mouse twice per week for 4 weeks. All mice were observed for tumor formation. Tumors were measured by calipers twice per week. FIG. 23G shows the matrigel invasion assay with the same cells performed in the presence and absence of purified monoclonal MUC16 Glycosylation Antibody 10C6 at 10 μg / mL. FIG. 23H demonstratess that differences in mean tumor volume were significantly decreased (p=0.0004) with monoclonal MUC16 Glycosylation Antibody 10C6-treated mice bearing MUC16<com:Sup>c344< / com:Sup> tumors compared with untreated MUC16<com:Sup>c344< / com:Sup> tumors, indicating protection against the effect of MUC16 on tumor growth.
[00187] FIG. 24A-FIG.24D depict galectin-mediated MUC16 protein-protein Interactions. FIG. 24A depicts immunoblot (IB) and immunoprecipitation (IP) of three glycosylated proteins (EGFR DDK-His; MUC16<com:Sup>c57-114< / com:Sup>-pFUSE; and LGALS3Myc-DDK). MUC16<com:Sup>c57-114< / com:Sup>-pFUSE glycosylated protein was combined with LGALS3 protein (0.13 µg) and EGFR (0.13 µg) and then rotated at 4 °C for 1 hour. Pre-blocked Protein A / G PLUS Agarose beads were added and were rotated at 4 °C overnight. IP pellets were washed extensively, boiled in loading buffer and separated by 10% SDS-PAGE gel electrophoresis, then transferred onto nitrocellulose membrane. The membrane was probed with anti-EGFR-v3, anti-4H11-HRP, or polyclonal anti- LGALS3 antibodies. As shown, the 4H11 binding showed that MUC16<com:Sup>c57-114< / com:Sup>-pFUSE was consistently present. LGALS3 bound in the lane positive for MUC16<com:Sup>c57-114< / com:Sup>-pFUSE, but EGFR was only detected when both LGALS3 and MUC16<com:Sup>c57-114< / com:Sup>-pFUSE were present. The presence of the monoclonal MUC16 Glycosylation Antibody 18C6 prevented the formation of these LGALS3, EGFR, and MUC16 protein complexes (right hand lanes). FIG. 24B depicts MUC16 and EGFR protein co-localization. Immunofluorescence staining of wild type OVCAR3 cells or SKOV3 cells transfected with phrGFP expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132; "SKOV3<com:Sup>c344< / com:Sup>") or with phrGFP expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133; "SKOV3<com:Sup>c114< / com:Sup>") with EGFR-A647 and 4H11-PE for MUC16, or a combination of both reagents EGFR-A647 and 4H11-PE for MUC16. Microscopic images (50 µm scale) indicated co-localization of EGFR and MUC16<com:Sup>c114< / com:Sup> in all three cell lines (see arrows). FIG. 24C depicts immunoblot (IB) and immunoprecipitation (IP) of three glycosylated proteins (Integrin β1Myc-DDK; MUC16<com:Sup>c57-114< / com:Sup>-pFUSE and LGALS3Myc- DDK). Generally the same methods as in FIG. 24A were used. Western blot analysis of immunoblot and all immunoprecipitated samples were run on 10% SDS-PAGE gel, transferred onto nitrocellulose membrane, and probed either with anti-4C5-DDK for Integrin β1, or anti- 4H11-HRP or anti-4C5-DDK for LGALS3 antibodies. As with EGFR, all three proteins were required to co-precipitate the Integrin β1 protein. The MUC16 Glycosylation Antibody 18C6 also blocked the combination of MUC16, LGALS3, and Integrin β1, as shown in the three right- hand lanes. FIG. 24D depicts MUC16 and Integrin β1 protein co-localization. Immunofluorescence staining of wild ty wild type OVCAR3 cells or SKOV3 cells transfected with phrGFP expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132; "SKOV3<com:Sup>c344< / com:Sup>") or with phrGFP expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133; "SKOV3<com:Sup>c114< / com:Sup>") with Integrin β1-A647 or 4H11-PE for MUC16 or a combination of both reagents Integrin β1-A647 or 4H11-PE for MUC16. Microscopic images (50 μm scale) indicated co-localization of the Integrin β1 and MUC16 in OVCAR3, SKOV3<com:Sup>c344< / com:Sup>, and SKOV3<com:Sup>c114< / com:Sup> cells (see arrows).
[00188] FIG. 25A depicts immunofluorescence staining of wild type OVCAR3 cells or SKOV3 cells transfected with phrGFP expressing MUC16<com:Sup>c344< / com:Sup> (SEQ ID NO: 132; "SKOV3<com:Sup>c344< / com:Sup>") or with phrGFP expressing MUC16<com:Sup>c114< / com:Sup> (SEQ ID NO: 133; "SKOV3<com:Sup>c114< / com:Sup>") or SKOV3<com:Sup>c344< / com:Sup> or SKOV3<com:Sup>c114< / com:Sup> cell lines with EGFR-A647 or 4H11-PE for MUC16 or a combination of both reagents. Microscopic images (scale 100 µm) clearly indicated co-localization of EGFR and MUC16 (see arrows). FIG. 25 B: Immunofluorescence staining of wild type OVCAR3 or SKOV3<com:Sup>c344< / com:Sup> or cell lines with Integrin β1-A647 or 4H11-PE for MUC16 or a combination of both reagents. Microscopic images (scale 100 μm) clearly indicated co-localization of Integrin β1 and MUC16 (see arrows).
[00189] FIG. 26A-FIG. 26D depicts a model of MUC16 Tumor Promotion. FIG. 26A depicts an illustration of EGFR-LGALS3-MUC16 and LGALS3-Integrin β1-MUC16 relationships. Signal transduction of SRC / ERK / AKT by EGFR or of SRC / FAK by Integrin β1 depended on MUC16 and signaling-molecule interaction with LGALS3 pentamers. FIG. 26B depicts a model for glycosylation loss: in shMGAT5-transfected cell lines, the N-glycosylation at sites on MUC16, EGFR, and Integrin β1 was reduced by loss of the tetra-antennary structures, resulting in no binding to LGALS3. FIG. 26C depicts a model for galectin-3 loss: in shLGALS3 transfected cell lines, while the N-glycosylation sites on MUC16 were present, the absence of binding to LGALS3 resulted in a loss of MUC16 / EGFR or MUC16 / Integrin β1 association and reduction of inside-out signals. FIG. 26D depicts a model for potential nhibitors for MUC16 / LGALS3 interactions. MUC16(+) cells exposed to MUC16 Glycosylation Antibody or "dummy" sham receptors (anti-MUC16<com:Sup>c57-114< / com:Sup>pFUSE or <com:Sup>117-244< / com:Sup>LGALS3-pFUSE) failed to bind to LGALS3 gels and subsequently also to either EGFR or Integrin β1.
[00190] FIG. 27A depicts the side-chain protected N-acetylated 55-mer peptide amide (SEQ) ID NO: 129). FIG. 27B depicts the ESI-MS and UV traces from UPLC analysis for glycopeptide p55-mer[N1-S55]. Calculated for <com:Math><semantics>C486H760N84O111S8<annotation encoding="application / x-tex">C_{486}H_{760}N_{84}O_{111}S_8< / annotation>< / semantics>< / com:Math>, 9812.25 (average isotopes) <com:Math><semantics>[M+5H]5+<annotation encoding="application / x-tex">[M+5H]^{5+}< / annotation>< / semantics>< / com:Math> m / z 1963.45, found 1963.20; <com:Math><semantics>[M+6H]6+<annotation encoding="application / x-tex">[M+6H]^{6+}< / annotation>< / semantics>< / com:Math> m / z 1636.38, found 1636.24; <com:Math><semantics>[M+7H]7+<annotation encoding="application / x-tex">[M+7H]^{7+}< / annotation>< / semantics>< / com:Math> m / z 1402.75, found 1402.74. BEH C4 column, gradient: 80-99% acetonitrile / water over 6 minutes at a flow rate of 0.3 mL / min.
[00191] FIG. 28A depicts the chitobiose-bearing 55-mer glycopeptide: "55- mer(chitobiose)[N1-S55]" (GlcNAc<com:Sub>2< / com:Sub>-55-mer) (SEQ ID NO: 129). FIG. 28B depicts the ESI-MS and UV traces from UPLC analysis for glycopeptide "55 mer(chitobiose) [N1-S55]" (GlcNAc<com:Sub>2< / com:Sub>- 55-mer). Calculated for <com:Math><semantics>C291H463N87O97S<annotation encoding="application / x-tex">C_{291}H_{463}N_{87}O_{97}S< / annotation>< / semantics>< / com:Math>, 6764.38 (average isotopes) <com:Math><semantics>[M+4H]4+<annotation encoding="application / x-tex">[M+4H]^{4+}< / annotation>< / semantics>< / com:Math> m / z 1692.10, found 1692.01; <com:Math><semantics>[M+5H]5+<annotation encoding="application / x-tex">[M+5H]^{5+}< / annotation>< / semantics>< / com:Math> m / z 1353.88, found 1353.86; <com:Math><semantics>[M+6H]6+<annotation encoding="application / x-tex">[M+6H]^{6+}< / annotation>< / semantics>< / com:Math> m / z 1128.40, found 1128.41; <com:Math><semantics>[M+7H]7+<annotation encoding="application / x-tex">[M+7H]^{7+}< / annotation>< / semantics>< / com:Math> m / z 967.34, found 967.45; <com:Math><semantics>[M+8H]8+<annotation encoding="application / x-tex">[M+8H]^{8+}< / annotation>< / semantics>< / com:Math> m / z 846.55, found 846.27. BEH C4 column, gradient: 20-40% acetonitrile / water over 6 minutes at a flow rate of 0.3 mL / min.
[00192] FIG. 29A depicts Man3GlcNAc2-bearing 55-mer glycopeptide: "55- mer(Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub>)[N1-S55]" (Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub>-55-mer) (SEQ ID NO: 129). FIG. 29B depicts the ESI-MS and UV traces from analytical HPLC analysis for glycopeptide "55" mer(Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub>)[N1-S55]" (Man<com:Sub>3< / com:Sub>GlcNAc<com:Sub>2< / com:Sub>-55-mer). Calculated for C<com:Sub>309< / com:Sub>H<com:Sub>493< / com:Sub>N<com:Sub>87< / com:Sub>O<com:Sub>112< / com:Sub>S, 7250.80 (average isotopes) <com:Math><semantics>[M+4H]4+<annotation encoding="application / x-tex">[M+4H]^{4+}< / annotation>< / semantics>< / com:Math> m / z 1813.70, found 1813.52; <com:Math><semantics>[M+5H]5+<annotation encoding="application / x-tex">[M+5H]^{5+}< / annotation>< / semantics>< / com:Math> m / z 1451.16, found 1451.02; [M+6H]<com:Sup>6+< / com:Sup> m / z 1209.47, found 1209.33; [M+7H]<com:Sup>7+< / com:Sup> m / z 1036.83, found 1036.74. Waters X-Bridge C18 column, gradient: 25-35% acetonitrile / water over 30 minutes at a flow rate of 0.2 mL / min.
[00193] FIG. 30A depicts side-chain protected 15-mer peptide (p15-mer[C-G25-V38]) (SEQ ID NO: 131). FIG. 30B depicts chitobiose-monoglycosylated 15-mer glycopeptide: 15- mer(chitobiose)[C-G25-V38] (GlcNAc<com:Sub>2< / com:Sub>-15-mer) (SEQ ID NO: 132). FIG. 30C depicts ESI-MS and UV traces from analytical HPLC analysis for glycopeptide "15 mer(chitobiose)[C-G25- V38]" (GlcNAc<com:Sub>2< / com:Sub>-15-mer). Calculated for <com:Math><semantics>C87H142N24O35S<annotation encoding="application / x-tex">C_{87}H_{142}N_{24}O_{35}S< / annotation>< / semantics>< / com:Math>, 2116.26 (average isotopes) <com:Math><semantics>[2M+3H]3+<annotation encoding="application / x-tex">[2M+3H]^{3+}< / annotation>< / semantics>< / com:Math> m / z 1411.84, found 1412.02; <com:Math><semantics>[M+2H]2+<annotation encoding="application / x-tex">[M+2H]^{2+}< / annotation>< / semantics>< / com:Math> m / z 1059.13, found 1059.15; <com:Math><semantics>[M+3H]3+<annotation encoding="application / x-tex">[M+3H]^{3+}< / annotation>< / semantics>< / com:Math> m / z 706.42, found 706.46. Varian Microsorb 300-5 C18 column, gradient: 15-30% acetonitrile / water over 30 minutes at a flow rate of 0.2 mL / min.
[00194] FIG. 31A depicts side-chain protected 18-mer peptide (p18-mer[C-G22-V38]) (AF- I-165) (SEQ ID NO: 130). FIG. 31B depicts chitobiose-bisglycosylated 18-mer glycopeptide: "18-mer(chitobiose)<com:Sub>2< / com:Sub>[C-T22-V38]" [(GlcNAc<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-18-mer] (SEQ ID NO: 130). FIG. 31C depicts the ESI-MS and UV traces from analytical HPLC analysis for glycopeptide "18 <com:Math><semantics>mer(chitobiose)2[C−T22−V38]<annotation encoding="application / x-tex">mer(chitobiose)_2[C-T22-V38]< / annotation>< / semantics>< / com:Math>" [(GlcNAc<com:Sub>2< / com:Sub>)<com:Sub>2< / com:Sub>-18-mer]. Calculated for <com:Math><semantics>C117H193N33O50S<annotation encoding="application / x-tex">C_{117}H_{193}N_{33}O_{50}S< / annotation>< / semantics>< / com:Math>, 2894.04 (average isotopes) <com:Math><semantics>[2M+3H]3+<annotation encoding="application / x-tex">[2M+3H]^{3+}< / annotation>< / semantics>< / com:Math> m / z 1930.36, found 1930.22; <com:Math><semantics>[M+2H]2+<annotation encoding="application / x-tex">[M+2H]^{2+}< / annotation>< / semantics>< / com:Math> m / z 1448.02, found 1447.65; <com:Math><semantics>[M+3H]3+<annotation encoding="application / x-tex">[M+3H]^{3+}< / annotation>< / semantics>< / com:Math> m / z 965.68, found 965.25. Varian Microsorb 300-5 C8 column, gradient: 15-30% acetonitrile / water over 30 minute at a flow rate of 0.2 mL / min.
[00195] FIG. 32A depicts glycopeptide "15-mer(chitobiose)[C-G25-V38]", conjugated to KLH (SEQ ID NO: 131). FIG. 32B depicts glycopeptide "18-mer(chitobiose)<com:Sub>2< / com:Sub>[C-T22-V38]" conjugated to KLH (SEQ ID NO: 130). 5. DETAILED DESCRIPTION
[00196] Provided are antibodies and antigen-binding fragments thereof, and polypeptides including such antibodies or fragments, such as fusion proteins, conjugates, and / or chimeric antigen receptors, as well as cells expressing the same. Among the antibodies and fragments are those that specifically bind to epitopes of a MUC16 protein. Such antibodies are referred to herein as "MUC16 Glycosylation Antibodies". Such epitopes are typically epitopes within or substantially within an extracellular portion of a MUC16 molecule, generally a non-shed form of MUC16; in some embodiments, the epitope is not within, or the antibody or fragment does not bind to, a tandem repeat region of MUC16 and / or a secreted form of MUC16. In some embodiments, the epitope is within or includes residues within MUC16c114, and typically includes one or more glycosylated residues or glycosylation sites therein. In some embodiments, the epitope includes one or more glycosylation sites, such as sites for N-glycosylation. In some aspects, the epitope includes an asparagine residue corresponding to Asn1806 or Asn1800 of the MUC16 sequence set forth in SEQ ID NO: 150 (and / or a glycosylated form(s) thereof); in some aspects, the epitope includes an asparagine residue corresponding to Asn1806 of SEQ ID NO: 150, but does not include an asparagine residue corresponding to Asn1800 of SEQ ID NO: 150; in some aspects, the epitope includes an asparagine residue corresponding to Asn1800 of SEQ ID NO: 150, but does not include an asparagine residue corresponding to Asn1806 of SEQ ID NO: 150. In some of any of such embodiments, such one or more asparagine is glycosylated, such as N-glycosylated. In some embodiments, the antibody or fragment binds to an epitope within or that includes residues within SEQ ID NO: 131; binds to an epitope within or that includes residues within SEQ ID NO: 130, or a combination thereof; in some embodiments, the antibody or fragment does not immunospecifically bind within a region of MUC16 corresponding to SEQ ID NO: 168, or within residues 2-19 of SEQ ID NO: 168.
[00197] In one aspect, provided herein are antibodies (e.g., monoclonal antibodies), and antigen-binding fragments thereof, that (i) immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lack immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibit matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16. In another aspect, provided herein are antibodies (e.g., monoclonal antibodies), and antigen-binding fragments thereof, that (i) immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lack immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO:139; and (iii) inhibit matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16. In a preferred embodiment, MUC16 Glycosylation Antibodies and antigen-binding fragments thereof described herein immunospecifically bind an epitope comprising amino acid residue 1806 (Asn1806) of SEQ ID NO:150, wherein Asn1806 is N-glycosylated (referred to herein as "Asn1806 Glycosylation"). As shown in the examples of Section 6 herein, Asn1806 Glycosylation is essential for MUC16- mediated invasion and growth of tumor cells. Thus, the MUC16 Glycosylation Antibodies and antigen-binding fragments thereof described herein are capable of binding blocking such invasion and growth of tumor cells.
[00198] In one embodiment, the MUC16 Glycosylation Antibody or antigen-binding fragment thereof requires an N-glycosylated Asn1800 in addition to an N-glycosylated Asn1806 for binding to MUC16 (i.e., both N-glycosylated sites are part of the epitope recognized by the MUC16 Glycosylation Antibody or antigen-binding fragment thereof). "Asn1800" refers to amino acid residue 1800 of SEQ ID NO:150. Such a MUC16 Glycosylation Antibody or antigen-binding fragment thereof can be identified by (i) its ability to immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; and (ii) its lack of immunospecific binding to a cell recombinantly expressing a fifth form of MUC16, which fifth form is glycosylated, and wherein the amino acid sequence of the fifth form is SEQ ID NO: 172, wherein the cell recombinantly expressing the first form of MUC16 is the same cell type as the cell recombinantly expressing the fifth form of MUC16.
[00199] In one embodiment, the MUC16 Glycosylation Antibody or antigen-binding fragment thereof requires an N-glycosylated Asn1806 but does not require an N-glycosylated Asn1800 for binding to MUC16 (i.e., N-glycosylated Asn1806 is part of the epitope recognized by the MUC16 Glycosylation Antibody or antigen-binding fragment thereof, but N-glycosylated Asn1800 is not part of the epitope recognized by the MUC16 Glycosylation Antibody or antigen- binding fragment thereof). Such a MUC16 Glycosylation Antibody or antigen-binding fragment thereof can be identified by (i) its ability to immunospecifically bind to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) its lack of immunospecific binding to a cell recombinantly expressing a third form of MUC16, which third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its ability to immunospecifically bind to a cell recombinantly expressing a fourth form of MUC16, which fourth form is glycosylated, and wherein the amino acid sequence of the fourth form is SEQ ID NO: 152; and (iii) wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same cell type.
[00200] The protein encoded by the amino acid sequence of SEQ ID NO:133 is also referred to herein as MUC16<com:Sup>c114< / com:Sup> and consists of the C-terminal 114 amino acid residues of mature MUC16 (SEQ ID NO: 150 being the sequence of mature MUC16). MUC16<com:Sup>c114< / com:Sup> is capable of being N-glycosylated at the asparagine amino acid residues at positions 1, 24, and 30 of SEQ ID NO: 133 (corresponding to amino acid positions Asn1777, Asn1800, and Asn1806 of SEQ ID NO: 150).
[00201] The protein encoded by the amino acid sequence of SEQ ID NO: 139 is also referred to herein as MUC16<com:Sup>c114-N3< / com:Sup>. MUC16<com:Sup>c114-N3< / com:Sup> consists of the C-terminal 114 amino acid residues of mature MUC16 (SEQ ID NO: 150 being the sequence of mature MUC16), except that the asparagine at amino acid position 30 (corresponding to amino acid position 1806 of SEQ ID NO: 150) has been mutated to an alanine. Thus, <com:Math><semantics>MUC16c114−N3<annotation encoding="application / x-tex">MUC16^{c114-N3}< / annotation>< / semantics>< / com:Math> is not capable of being N-glycosylated at amino acid position 30 of SEQ ID NO: 139 (corresponding to amino acid position Asn1806 of SEQ ID NO: 150).
[00202] The protein encoded by the amino acid sequence of SEQ ID NO: 152 is also referred to herein as MUC16<com:Sup>c114-N2< / com:Sup>. MUC16<com:Sup>c114-N2< / com:Sup> consists of the C-terminal 114 amino acid residues of mature MUC16 (SEQ ID NO:150 being the sequence of mature MUC16), except that the asparagine at amino acid position 24 (corresponding to amino acid position Asn1800 of SEQ ID NO: 150) has been mutated to an alanine. Thus, <com:Math><semantics>MUC16c114−N2<annotation encoding="application / x-tex">MUC16^{c114-N2}< / annotation>< / semantics>< / com:Math> is not capable of being N- glycosylated at amino acid position 24 of SEQ ID NO: 152 (corresponding to amino acid position Asn1800 of SEQ ID NO: 150).
[00203] The protein encoded by the amino acid sequence of SEQ ID NO: 172 is also referred to herein as MUC16<com:Sup>c114-N23< / com:Sup>. MUC16<com:Sup>c114-N23< / com:Sup> consists of the C-terminal 114 amino acid residues of mature MUC16 (SEQ ID NO:150 being the sequence of mature MUC16), except that the asparagines at amino acid positions 24 and 30 (corresponding to amino acid positions Asn1800 and Asn1806 of SEQ ID NO: 150) have been mutated to alanines. Thus, MUC16<com:Sup>c114-N23< / com:Sup> is not capable of being N-glycosylated at amino acid positions 24 and 30 of SEQ ID NO: 157 (corresponding to amino acid positions Asn1800 and Asn1806 of SEQ ID NO: 150).
[00204] Also provided herein are heavy chains and light chains, wherein a MUC16 Glycosylation Antibody or antigen binding fragment thereof comprising said heavy and light chains (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16. Also provided herein are polynucleotides (e.g., isolated polynucleotides) comprising nucleic acid sequences (e.g., complementary DNA (cDNA)), encoding such antibodies, and antigen-binding fragments thereof, heavy chains, or light chains. Further provided are vectors (e.g., expression vectors) and cells (e.g., isolated cells or ex vivo cells) comprising polynucleotides (e.g., isolated polynucleotides) comprising nucleic acid sequences (e.g., complementary DNA (cDNA)), encoding such antibodies, and antigen- binding fragments thereof, heavy chains, or light chains. Also provided are methods of making such antibodies, antigen-binding fragments thereof, heavy chains, light chains, vectors, and cells. In other aspects, provided herein are methods and uses for MUC16 activity and / or MUC16- driven tumor growth, or treating or managing certain conditions or disorders described herein, such as treating or managing cancer. Related compositions (e.g., pharmaceutical compositions), kits, and diagnostic methods are also provided.
[00205] As used herein, the term "MUC16" or "MUC16 polypeptide" or "MUC16 peptide" refers to the MUC16 tethered mucin protein as described in Yin BW and Lloyd KO, 2001, J Biol Chem. 276(29):27371-5. GenBank<com:Sup>TM< / com:Sup> accession number NM 024690.2 (SEQ ID NO:137) provides an exemplary human MUC16 nucleic acid sequence. GenBank<com:Sup>TM< / com:Sup> accession number NP 078966.2 (SEQ ID NO:136) provides an exemplary human MUC16 amino acid sequence. Native MUC16 comprises an intracellular domain, a transmembrane domain, an ectodomain proximal to the putative cleavage site, and a large, heavily glycosylated region of 12-20 repeats, each 156 amino acids long (FIG. 1A). "Immature" MUC16 refers to SEQ ID NO:136, which comprises the MUC16 signal sequence (amino acid residues 1-60 of SEQ ID NO:136). "Mature MUC16" refers to native MUC16 as expressed on the cell surface, i.e., where the signal sequence has been removed by cellular processing, for example, SEQ ID NO:150, where the first 60 amino acid residues of SEQ ID NO:136 have been removed (i.e., SEQ ID NO:136 is the "immature" form of MUC16).
[00206] With respect to antibody names, (i) 18C6 and 18C6.D12 are used interchangeably, (ii) 10C6 and 10C6.E4 are used interchangeably, (iii) 19C11 and 19C11.H6 are used interchangeably, and (iv) 7B12 and 7B12.B3 are used interchangeably. The antibody subclones (i.e., 18C6.D12, 10C6.E4, 19C11.H6, and 7B12.B3) were used in the experiments described in Section 6. 5.1 ANTIBODIES
[00207] MUC16 Glycosylation Antibodies or antigen-binding fragments thereof can include, e.g., monoclonal antibodies, polyclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain- antibody heavy chain pair, intrabodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain variable fragments (scFv), camelized antibodies, affybodies, and disulfide-linked Fvs (dsFv), or fragments thereof. Such antibodies can be made by methods known in the art.
[00208] A multispecific antibody or fragment thereof refers to an antibody or fragment thereof that can bind simultaneously to at least two targets that are of different structure, e.g., two different antigens, two different epitopes on the same antigen, or a hapten and an antigen or epitope. One specificity could be for, for example, a B-cell, T-cell, myeloid-, plasma-, or mast- cell antigen or epitope, such as, for example CD3. Another specificity could be to a different antigen on the same or different cell type, such as for example, MUC16. Multispecific, multivalent antibodies are constructs that have more than one binding site, and the binding sites are of different specificity, for example, a bispecific diabody, where one binding site reacts with one antigen and the other with another antigen.
[00209] A bispecific antibody is an antibody that can bind simultaneously to two targets which are of different structure. Bispecific antibodies (bsAb) and bispecific antibody fragments (bsFab) have at least one arm that immunospecifically binds to a first target, for example, MUC16, and at least one other arm that immunospecifically binds to a second target, such as, for example, CD3. A variety of bispecific fusion proteins can be produced using molecular engineering. In one form, the bispecific fusion protein is divalent, consisting of, for example, (i) a scFv with a single binding site for one antigen and (ii) an antibody or a Fab fragment with a single binding site for a second antigen. In another form, the bispecific fusion protein is tetravalent, consisting of, for example, an IgG with two binding sites for one antigen and two identical scFv for a second antigen. See, for example, International Publication No. WO 2011 / 1160119.
[00210] Recent methods for producing bispecific monoclonal antibodies include the use of engineered recombinant monoclonal antibodies which have additional cysteine residues so that they crosslink more strongly than the more common immunoglobulin isotypes. See, e.g., FitzGerald et al., Protein Eng. 10(10):1221-1225, 1997. Another approach is to engineer recombinant fusion proteins linking two or more different single-chain antibody or antibody fragment segments with the needed dual specificities. See, e.g., Coloma et al., Nature Biotech. 15:159-163, 1997. A variety of bispecific fusion proteins can be produced using molecular engineering.
[00211] Bispecific fusion proteins linking two or more different single-chain antibodies or antibody fragments can be produced in similar manner. Recombinant methods can be used to produce a variety of fusion proteins. In certain aspects, a flexible linker connects an scFv (e.g., an scFv targeting CD3) to the constant region of the light chain of a monoclonal antibody (e.g., a MUC16 Glycosylation Antibody described herein; see Section 5.1). Appropriate linker sequences necessary for the in-frame connection of the heavy chain Fc to the scFv are introduced into the VL and Vkappa domains through PCR reactions. The DNA fragment encoding the scFv is then ligated into a staging vector containing a DNA sequence encoding the CHI domain. The resulting construct is excised and ligated into a vector containing a DNA sequence encoding the VH region of the antibody (e.g., the MUC16 Glycosylation Antibody). The resulting vector can be used to transfect an appropriate host cell, such as a mammalian cell for the expression of the bispecific fusion protein.
[00212] The MUC16 Glycosylation Antibodies described herein (see Section 5.1) and fragments thereof in certain embodiments can also be used to prepare functional bispecific single-chain antibodies (bscAb), also called diabodies, and can be produced in mammalian cells using recombinant methods. See, e.g., Mack et al., Proc. Natl. Acad. Sci., 92: 7021-7025, 1995. For example, bscAb can be produced by joining two single-chain Fv fragments via a glycine-serine linker using recombinant methods. The VL and VH domains of two antibodies of interest are isolated using standard PCR methods known in the art. Bispecific single-chain antibodies and bispecific fusion proteins are included within the scope of the present invention.
[00213] In certain embodiments, MUC16 Glycosylation Antibodies or antigen-binding fragments thereof described herein refer to scFvs. A scFv is an art-recognized term. An scFv comprises a fusion protein of the variable regions of the heavy (VH) and light (VL) chains of an immunoglobulin, wherein the fusion protein retains the same antigen specificity as the whole immunoglobulin. The VH is fused to the VL via a peptide linker. In certain embodiments, the peptide linker is between 5 and 25, 5 and 15, 10 and 20, 10 and 15, or 15 and 25 amino acid residues in length. In certain embodiments, the scFv peptide linker displays one or more characteristics suitable for a peptide linker known to one of ordinary skill in the art. In certain embodiments, the scFv peptide linker comprises amino acids that allow for scFv peptide linker solubility, such as, for example, serine and threonine. In certain embodiments, the scFv peptide linker comprises amino acids that allow for scFv peptide linker flexibility, such as, for example, glycine. In certain embodiments, the scFv peptide linker connects the N-terminus of the VH to the C-terminus of the VL. In certain embodiments, the scFv peptide linker can connect the C- terminus of the VH to the N-terminus of the VL.
[00214] In certain embodiments, MUC16 Glycosylation Antibodies or antigen-binding fragments thereof described herein refer to chimeric antigen receptors (CARs). A CAR is an art- recognized term. A CAR can be targeted to a tumor associated antigen (e.g., MUC16). CARs as provided herein typically are composed of a scFv derived from a MUC16 Glycosylation Antibody, a transmembrane domain, which in some embodiments is a T cell co-stimulatory molecule-derived transmembrane domain (for example, a transmembrane domain derived from CD28, CD8, CD38, OX-40, or 4-1BB), and a primary signaling domain, such as the T cell receptor (TCR) zeta (<com:Math><semantics>ζ<annotation encoding="application / x-tex">\zeta< / annotation>< / semantics>< / com:Math>) chain cytoplasmic signaling domain. In some embodiments, the CAR further includes one or more additional regions or domains such as one or more spacer or linker, including an extracellular spacer, such as one derived from an antibody or other cell-surface molecule, such as a spacer containing gone or more of antibody CH2, CH3, and / or hinge regions, or a spacer derived from a CD28 molecule or a CD8 molecule, or other spacer. Also provided herein are cells, such as T cells engineered to express such CARs, such as those recombinantly expressing such a CAR. A CAR-expressing T cell, upon recognition of a MUC16 expressing tumor, preferably induces T cell activation, proliferation, and / or lysis of a cell of such a tumor.
[00215] MUC16 Glycosylation Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY), any class (e.g., IgG<com:Sub>1< / com:Sub>, IgG<com:Sub>2< / com:Sub>, IgG<com:Sub>3< / com:Sub>, IgG<com:Sub>4< / com:Sub>, IgA<com:Sub>1< / com:Sub> or IgA<com:Sub>2< / com:Sub>), or any subclass (e.g., IgG<com:Sub>2a< / com:Sub> or <com:Math><semantics>IgG2b<annotation encoding="application / x-tex">IgG_{2b}< / annotation>< / semantics>< / com:Math>) of immunoglobulin molecule. In certain embodiments, antibodies described herein are IgG antibodies, or a class or subclass thereof. In certain embodiments, antibodies described herein are IgG<com:Sub>1< / com:Sub> antibodies. In certain embodiments, antibodies described herein are IgG<com:Sub>2< / com:Sub> antibodies. In certain embodiments, antibodies described herein are <com:Math><semantics>IgG2a<annotation encoding="application / x-tex">IgG_{2a}< / annotation>< / semantics>< / com:Math> antibodies. In certain embodiments, antibodies described herein are IgG<com:Sub>2b< / com:Sub> antibodies. In certain embodiments, antibodies described herein are a mixture of IgG<com:Sub>2a< / com:Sub> and IgG<com:Sub>2b< / com:Sub> antibodies. In a specific embodiment, the antibody is a humanized form of a rodent monoclonal antibody.
[00216] In a specific embodiment, the antigen to which the MUC16 Glycosylation Antibody or antigen-binding fragment thereof binds, is a form of MUC16 which is glycosylated, for example, wherein the amino acid sequence of the form of MUC16 is SEQ ID NO:133. The protein encoded by the amino acid sequence of SEQ ID NO:133 is also referred to herein as MUC16<com:Sup>c114< / com:Sup> and consists of the C-terminal 114 amino acid residues of mature MUC16. MUC16<com:Sup>c114< / com:Sup> is capable of being N-glycosylated at the asparagine amino acids of positions 1, 24, and 30 of SEQ ID NO: 133 (corresponding to amino acid positions Asn1777, Asn1800, and Asn1806 of SEQ ID NO: 150). Mature MUC16 (SEQ ID NO:150) refers to full length MUC16 wherein the signal sequence has been removed, and wherein the signal sequence consists of the first 60 amino acid residues of SEQ ID NO:136 (i.e., SEQ ID NO:136 is the "immature" form of MUC16).
[00217] Antigen binding fragments of MUC16 Glycosylation Antibodies can be Fab fragments, F(ab')<com:Sub>2< / com:Sub> fragments, or a portion of MUC16 Glycosylation Antibody which comprises the amino acid residues that confer on the MUC16 Glycosylation Antibody its specificity for the antigen (e.g., the complementarity determining regions (CDR)). The MUC16 Glycosylation Antibody can be derived from any animal species, such as rodents (e.g., mouse, rat or hamster) and humans.
[00218] As used herein, the terms "variable region" or "variable domain" are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids in a mature heavy chain and about the amino-terminal 90 to 100 amino acids in a mature light chain, which differs extensively in sequence among antibodies and is used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). CDRs are flanked by FRs. Generally, the spatial orientation of CDRs and FRs are as follows, in an N-terminal to C-terminal direction: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen. In certain embodiments, the variable region is a rodent (e.g., mouse or rat) variable region. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent (e.g., mouse or rat) CDRs and human framework regions (FRs). In particular embodiments, the variable region is a primate (e.g., non- human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs).
[00219] CDRs are defined in various ways in the art, including the Kabat, Chothia, and IMGT, and Exemplary definitions. The Kabat definition is based on sequence variability (Kabat, Elvin A. et al., Sequences of Proteins of Immunological Interest. Bethesda: National Institutes of Health, 1983). With respect to the Kabat numbering system, (i) the VH CDR1 is typically present at amino acid positions 31 to 35 of the heavy chain, which can optionally include one or two additional amino acids following amino acid position 35 (referred to in the Kabat numbering scheme as 35A and 35B); (ii) the VH CDR2 is typically present at amino acid positions 50 to 65 of the heavy chain; and (iii) the VH CDR2 is typically present at amino acid positions 95 to 102 of the heavy chain (Kabat, Elvin A. et al., Sequences of Proteins of Immunological Interest. Bethesda: National Institutes of Health, 1983). With respect to the Kabat numbering system, (i) the VL CDR1 is typically present at amino acid positions 24 to 34 of the light chain; (ii) the VL CDR2 is typically present at amino acid positions 50 to 56 of the light chain; and (iii) the VL CDR3 is typically present at amino acid positions 89 to 97 of the light chain (Kabat, Elvin A. et al., Sequences of Proteins of Immunological Interest. Bethesda: National Institutes of Health, 1983). As is well known to those of skill in the art, using the Kabat numbering system, the actual linear amino acid sequence of the antibody variable domain can contain fewer or additional amino acids due to a shortening or lengthening of a FR and / or CDR and, as such, an amino acid's Kabat number is not necessarily the same as its linear amino acid number.
[00220] The Chothia definition is based on the location of the structural loop regions (Chothia et al., (1987) J Mol Biol 196: 901-917; and U.S. Patent No. 7,709,226). The term "Chothia" CDRs," and like terms are recognized in the art and refer to antibody CDR sequences as determined according to the method of Chothia and Lesk, 1987, J. Mol. Biol., 196:901-917, which will be referred to herein as the "Chothia CDRs" (see also, e.g., U.S. Patent No. 7,709,226 and Martin, A., "Protein Sequence and Structure Analysis of Antibody Variable Domains," in Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001)). With respect to the Chothia numbering system, using the Kabat numbering system of numbering amino acid residues in the VH region, (i) the VH CDR1 is typically present at amino acid positions 26 to 32 of the heavy chain; (ii) the VH CDR2 is typically present at amino acid positions 53 to 55 of the heavy chain; and (iii) the VH CDR3 is typically present at amino acid positions 96 to 101 of the heavy chain. In a specific embodiment, with respect to the Chothia numbering system, using the Kabat numbering system of numbering amino acid residues in the VH region, (i) the VH CDR1 is typically present at amino acid positions 26 to 32 or 34 of the heavy chain; (ii) the VH CDR2 is typically present at amino acid positions 52 to 56 (in one embodiment, CDR2 is at positions 52A-56, wherein 52A follows position 52) of the heavy chain; and (iii) the VH CDR3 is typically present at amino acid positions 95 to 102 of the heavy chain (in one embodiment, there is no amino acid at positions numbered 96-100). With respect to the Chothia numbering system, using the Kabat numbering system of numbering amino acid residues in the VL region, (i) the VL CDR1 is typically present at amino acid positions 26 to 33 of the light chain; (ii) the VL CDR2 is typically present at amino acid positions 50 to 52 of the light chain; and (iii) the VL CDR3 is typically present at amino acid positions 91 to 96 of the light chain. In a specific embodiment, with respect to the Chothia numbering system, using the Kabat numbering system of numbering amino acid residues in the VL region, (i) the VL CDR1 is typically present at amino acid positions 24 to 34 of the light chain; (ii) the VL CDR2 is typically present at amino acid positions 50 to 56 of the light chain; and (iii) the VL CDR3 is typically present at amino acid positions 89 to 97 of the light chain (in one embodiment, there is no amino acid at positions numbered 96-100). These Chothia CDR positions may vary depending on the antibody, and may be determined according to methods known in the art.
[00221] The IMGT definition is from the IMGT ("IMGT®, the international ImMunoGeneTics information system® website imgt.org, founder and director: Marie-Paule Lefranc, Montpellier, France; see, e.g., Lefranc, M.-P., 1999, The Immunologist, 7:132-136 and Lefranc, M.-P. et al., 1999, Nucleic Acids Res., 27:209-212). With respect to the IMGT numbering system, (i) the VH CDR1 is typically present at amino acid positions 25 to 35 of the heavy chain; (ii) the VH CDR2 is typically present at amino acid positions 51 to 57 of the heavy chain; and (iii) the VH CDR2 is typically present at amino acid positions 93 to 102 of the heavy chain. With respect to the IMGT numbering system, (i) the VL CDR1 is typically present at amino acid positions 27 to 32 of the light chain; (ii) the VL CDR2 is typically present at amino acid positions 50 to 52 of the light chain; and (iii) the VL CDR3 is typically present at amino acid positions 89 to 97 of the light chain. 5.1.1 SEQUENCES AND STRUCTURES
[00222] In certain embodiments, provided herein is a MUC16 Glycosylation Antibody or antigen-binding fragment thereof which comprises VH CDRs of any of the MUC16 Glycosylation Antibodies provided herein, e.g., as set forth in Tables 1, 3, and 5. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises the VH CDR1 of a MUC16 Glycosylation Antibody as set forth in Table 1, 3, or 5. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises the VH CDR2 of a MUC16 Glycosylation Antibody as set forth in Table 1, 3, or 5. In certain embodiments, a MUC16 Glycosylation Antibody or antigen- binding fragment thereof provided herein comprises the VH CDR3 of a MUC16 Glycosylation Antibody as set forth in Table 1, 3, or 5. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises one, two or all three of VH CDRs of a MUC16 Glycosylation Antibody as set forth in Table 1, 3, or 5 (e.g., the VL CDRs in row two of Table 1, e.g., all of the VH CDRs for antibody 10C6)
[00223] In certain embodiments, provided herein is a MUC16 Glycosylation Antibody or antigen-binding fragment thereof which comprises VL CDRs of any of the anti-MUC16 antibodies provided herein, e.g., as set forth in Tables 2, 4, and 6. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises the VH CDR1 of a MUC16 Glycosylation Antibody as set forth in Table 2, 4, or 6. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises the VH CDR2 of a MUC16 Glycosylation Antibody as set forth in Table 2, 4, or 6. In certain embodiments, an anti-MUC16 antibody or antigen-binding fragment thereof provided herein comprises the VH CDR3 of a MUC16 Glycosylation Antibody as set forth in Table 2, 4, or 6. In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof provided herein comprises one, two or all three of VL CDRs of a MUC16 Glycosylation Antibody in Table 2, 4, or 6 (e.g., the VL CDRs in row two of Table 2, e.g., all of the VH CDRs for antibody 10C6)
[00224] Table 1. VH CDR Amino Acid Sequences (Kabat). [Image disponible dans le document PDF, Image available in the PDF document]
[00225] Table 2. VL CDR Amino Acid Sequences (Kabat). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]
[00226] Table 3. VH CDR Amino Acid Sequences (Chothia). [Image disponible dans le document PDF, Image available in the PDF document]
[00227] Table 4. VL CDR Amino Acid Sequences (Chothia). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]
[00228] Table 5. VH CDR Amino Acid Sequences (IMGT). [Image disponible dans le document PDF, Image available in the PDF document]
[00229] Table 6. VL CDR Amino Acid Sequences (IMGT). [Image disponible dans le document PDF, Image available in the PDF document]
[00230] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein, comprises a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein <com:Math><semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>< / com:Math> is E or absent, and <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105).
[00231] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> is N or S, and <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111).
[00232] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S.
[00233] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17.
[00234] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37.
[00235] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57.
[00236] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77.
[00237] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97.
[00238] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein <com:Math><semantics>X4<annotation encoding="application / x-tex">X_4< / annotation>< / semantics>< / com:Math> is R or L, and <com:Math><semantics>X5<annotation encoding="application / x-tex">X_5< / annotation>< / semantics>< / com:Math> is K or H; (b) a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and (c) a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein <com:Math><semantics>X6<annotation encoding="application / x-tex">X_6< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X7<annotation encoding="application / x-tex">X_7< / annotation>< / semantics>< / com:Math> is H or Y.
[00239] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SKSLX<com:Sub>11< / com:Sub>X<com:Sub>12< / com:Sub>SNGNTY (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and (c) a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y.
[00240] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises: (a) a VL complementarity determining region (CDR)1 comprising the amino acid sequence KSLX<com:Sub>19< / com:Sub>X<com:Sub>20< / com:Sub>SNGNTY (SEQ ID NO:118), wherein X<com:Sub>19< / com:Sub> is V or L, and X<com:Sub>20< / com:Sub> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and (c) a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120).
[00241] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20.
[00242] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40.
[00243] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60.
[00244] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
[00245] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100.
[00246] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises: (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein <com:Math><semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>< / com:Math> is E or absent and wherein <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence RSSKSLX<com:Sub>4< / com:Sub>X<com:Sub>5< / com:Sub>SNGNTYLY (SEQ ID NO:106), wherein <com:Math><semantics>X4<annotation encoding="application / x-tex">X_4< / annotation>< / semantics>< / com:Math> is R or L, and wherein <com:Math><semantics>X5<annotation encoding="application / x-tex">X_5< / annotation>< / semantics>< / com:Math> is K or H; (b) a VL CDR2 comprising the amino acid sequence YMSNLAS (SEQ ID NO:107); and (c) a VL CDR3 comprising the amino acid sequence MQX<com:Sub>6< / com:Sub>LEX<com:Sub>7< / com:Sub>PLT (SEQ ID NO:108), wherein <com:Math><semantics>X6<annotation encoding="application / x-tex">X_6< / annotation>< / semantics>< / com:Math> is G or S and wherein <com:Math><semantics>X7<annotation encoding="application / x-tex">X_7< / annotation>< / semantics>< / com:Math> is H or Y.
[00247] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SKSLX<com:Sub>11< / com:Sub>X<com:Sub>12< / com:Sub>SNGNTY (SEQ ID NO:112), wherein <com:Math><semantics>X11<annotation encoding="application / x-tex">X_{11}< / annotation>< / semantics>< / com:Math> is L or R, and wherein <com:Math><semantics>X12<annotation encoding="application / x-tex">X_{12}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:113); and (c) a VL CDR3 comprising the amino acid sequence <com:Math><semantics>X13LEX14PL<annotation encoding="application / x-tex">X_{13}LEX_{14}PL< / annotation>< / semantics>< / com:Math> (SEQ ID NO:114), wherein <com:Math><semantics>X13<annotation encoding="application / x-tex">X_{13}< / annotation>< / semantics>< / com:Math> is G or S, and wherein <com:Math><semantics>X14<annotation encoding="application / x-tex">X_{14}< / annotation>< / semantics>< / com:Math> is H or Y.
[00248] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S; and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence KSLX<com:Sub>19< / com:Sub>X<com:Sub>20< / com:Sub>SNGNTY (SEQ ID NO:118), wherein <com:Math><semantics>X19<annotation encoding="application / x-tex">X_{19}< / annotation>< / semantics>< / com:Math> is V or L, and wherein <com:Math><semantics>X20<annotation encoding="application / x-tex">X_{20}< / annotation>< / semantics>< / com:Math> is H or K; (b) a VL CDR2 comprising the amino acid sequence YMS (SEQ ID NO:119); and (c) a VL CDR3 comprising the amino acid sequence MQSLEYPLT (SEQ ID NO:120).
[00249] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises: (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein <com:Math><semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>< / com:Math> is E or absent and wherein <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SEQ ID NO:6; (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7; and (c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8.
[00250] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SEQ ID NO:12; (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13; and (c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14.
[00251] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S; and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SEQ ID NO:18; (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19; and (c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20.
[00252] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence TX<com:Sub>1< / com:Sub>GMGVG (SEQ ID NO:103), wherein <com:Math><semantics>X1<annotation encoding="application / x-tex">X_1< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence HIWWDDX<com:Sub>2< / com:Sub>DKYYX<com:Sub>3< / com:Sub>PALKS (SEQ ID NO:104), wherein <com:Math><semantics>X2<annotation encoding="application / x-tex">X_2< / annotation>< / semantics>< / com:Math> is E or absent and wherein <com:Math><semantics>X3<annotation encoding="application / x-tex">X_3< / annotation>< / semantics>< / com:Math> is Y or N; and (c) a VH CDR3 comprising the amino acid sequence IGTAQATDALDY (SEQ ID NO:105); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SEQ ID NO:26; (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27; and (c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28.
[00253] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises: (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>8< / com:Sub>TX<com:Sub>9< / com:Sub>GM (SEQ ID NO:109), wherein <com:Math><semantics>X8<annotation encoding="application / x-tex">X_8< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X9<annotation encoding="application / x-tex">X_9< / annotation>< / semantics>< / com:Math> is L or V; (b) a VH CDR2 comprising the amino acid sequence WDDX<com:Sub>10< / com:Sub> (SEQ ID NO:110), wherein <com:Math><semantics>X10<annotation encoding="application / x-tex">X_{10}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence GTAQATDALD (SEQ ID NO:111); and (ii) a VL which comprises: (a) a VL CDR1 comprising the amino acid sequence SEQ ID NO:32; (b) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33; and (c) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34.
[00254] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises: (i) a VH which comprises: (a) a VH CDR1 comprising the amino acid sequence GFSLX<com:Sub>15< / com:Sub>TX<com:Sub>16< / com:Sub>GMG (SEQ ID NO:115), wherein <com:Math><semantics>X15<annotation encoding="application / x-tex">X_{15}< / annotation>< / semantics>< / com:Math> is N or S, and wherein <com:Math><semantics>X16<annotation encoding="application / x-tex">X_{16}< / annotation>< / semantics>< / com:Math> is V or L; (b) a VH CDR2 comprising the amino acid sequence IWWDDX<com:Sub>17< / com:Sub>DK (SEQ ID NO:116), wherein <com:Math><semantics>X17<annotation encoding="application / x-tex">X_{17}< / annotation>< / semantics>< / com:Math> is E or absent; and (c) a VH CDR3 comprising the amino acid sequence <com:Math><semantics>X18RIGTAQATDALDY<annotation encoding="application / x-tex">X_{18}RIGTAQATDALDY< / annotation>< / semantics>< / com:Math> (SEQ ID NO:117), wherein <com:Math><semantics>X18<annotation encoding="application / x-tex">X_{18}< / annotation>< / semantics>< / com:Math> is T, A, or S; and (ii) a VL which comprises: (d) a VL CDR1 comprising the amino acid sequence SEQ ID NO:38; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40.
[00255] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; and (b) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; and (b) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20.
[00256] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; and (b) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40.
[00257] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60.
[00258] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
[00259] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94. In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH which comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97; and (b) a VL which comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100.
[00260] Table 7. VH Domain Amino Acid Sequences [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]
[00261] Table 8. VL Domain Amino Acid Sequences [Image disponible dans le document PDF, Image available in the PDF document]
[00262] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH region comprising [Image disponible dans le document PDF, Image available in the PDF document] IWWDDX<com:Sub>27< / com:Sub>DKYYX<com:Sub>28< / com:Sub>PALKSRLTISX<com:Sub>29< / com:Sub>X<com:Sub>30< / com:Sub>X<com:Sub>31< / com:Sub>SKNQVFLKIX<com:Sub>32< / com:Sub>NVX<com:Sub>33< / com:Sub>TADX<com:Sub>34< / com:Sub>ATYYCX<com:Sub>35< / com:Sub>RI GTAQATDALDYWGQGTSVTVSS (SEQ ID NO:101), wherein X<com:Sub>21< / com:Sub> is T or N, X<com:Sub>22< / com:Sub> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A.
[00263] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL region comprising DIVMTQAAPSX<com:Sub>36< / com:Sub>X<com:Sub>37< / com:Sub>VTPGESVSISCRSSKSLX<com:Sub>38< / com:Sub>X<com:Sub>39< / com:Sub>SNGNTYLYWFLQRPGQSPQRLIYY MSNLASGVPDRFSGRGSGTDFTLX<com:Sub>40< / com:Sub>ISRVEAX<com:Sub>41< / com:Sub>DVGVYYCMQX<com:Sub>42< / com:Sub>LEX<com:Sub>43< / com:Sub>PLTFGGGTKL EIK (SEQ ID NO: 102), wherein <com:Math><semantics>X36<annotation encoding="application / x-tex">X_{36}< / annotation>< / semantics>< / com:Math> is I or V, <com:Math><semantics>X37<annotation encoding="application / x-tex">X_{37}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X38<annotation encoding="application / x-tex">X_{38}< / annotation>< / semantics>< / com:Math> is R or L, <com:Math><semantics>X39<annotation encoding="application / x-tex">X_{39}< / annotation>< / semantics>< / com:Math> is K or H, <com:Math><semantics>X40<annotation encoding="application / x-tex">X_{40}< / annotation>< / semantics>< / com:Math> is R or K, <com:Math><semantics>X41<annotation encoding="application / x-tex">X_{41}< / annotation>< / semantics>< / com:Math> is E or G, <com:Math><semantics>X42<annotation encoding="application / x-tex">X_{42}< / annotation>< / semantics>< / com:Math> is S or G, and <com:Math><semantics>X43<annotation encoding="application / x-tex">X_{43}< / annotation>< / semantics>< / com:Math> is Y or H.
[00264] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) VH region comprising [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein <com:Math><semantics>X21<annotation encoding="application / x-tex">X_{21}< / annotation>< / semantics>< / com:Math> is T or N, <com:Math><semantics>X22<annotation encoding="application / x-tex">X_{22}< / annotation>< / semantics>< / com:Math> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A; and (b) a VL region comprising DIVMTQAAPSX<com:Sub>36< / com:Sub>X<com:Sub>37< / com:Sub>VTPGESVSISCRSSKSLX<com:Sub>38< / com:Sub>X<com:Sub>39< / com:Sub>SNGNTYLYWFLQRPGQSP QRLIYYMSNLASGVPDRFSGRGSGTDFTLX<com:Sub>40< / com:Sub>ISRVEAX<com:Sub>41< / com:Sub>DVGVYYCMQX<com:Sub>42< / com:Sub>LE X<com:Sub>43< / com:Sub>PLTFGGGTKLEIK (SEQ ID NO:102), wherein X<com:Sub>36< / com:Sub> is I or V, X<com:Sub>37< / com:Sub> is P or S, X<com:Sub>38< / com:Sub> is R or L, <com:Math><semantics>X39<annotation encoding="application / x-tex">X_{39}< / annotation>< / semantics>< / com:Math> is K or H, <com:Math><semantics>X40<annotation encoding="application / x-tex">X_{40}< / annotation>< / semantics>< / com:Math> is R or K, <com:Math><semantics>X41<annotation encoding="application / x-tex">X_{41}< / annotation>< / semantics>< / com:Math> is E or G, <com:Math><semantics>X42<annotation encoding="application / x-tex">X_{42}< / annotation>< / semantics>< / com:Math> is S or G, and <com:Math><semantics>X43<annotation encoding="application / x-tex">X_{43}< / annotation>< / semantics>< / com:Math> is Y or H.
[00265] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) VH region comprising [Image disponible dans le document PDF, Image available in the PDF document] wherein <com:Math><semantics>X21<annotation encoding="application / x-tex">X_{21}< / annotation>< / semantics>< / com:Math> is T or N, <com:Math><semantics>X22<annotation encoding="application / x-tex">X_{22}< / annotation>< / semantics>< / com:Math> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A; and (b) a VL region comprising the amino acid sequence of SEQ ID NO:2.
[00266] In a particular embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) VH region comprising [Image disponible dans le document PDF, Image available in the PDF document] wherein <com:Math><semantics>X21<annotation encoding="application / x-tex">X_{21}< / annotation>< / semantics>< / com:Math> is T or N, <com:Math><semantics>X22<annotation encoding="application / x-tex">X_{22}< / annotation>< / semantics>< / com:Math> is I or K, <com:Math><semantics>X23<annotation encoding="application / x-tex">X_{23}< / annotation>< / semantics>< / com:Math> is N or S, <com:Math><semantics>X24<annotation encoding="application / x-tex">X_{24}< / annotation>< / semantics>< / com:Math> is V or L, <com:Math><semantics>X25<annotation encoding="application / x-tex">X_{25}< / annotation>< / semantics>< / com:Math> is S or I, <com:Math><semantics>X26<annotation encoding="application / x-tex">X_{26}< / annotation>< / semantics>< / com:Math> is P or S, <com:Math><semantics>X27<annotation encoding="application / x-tex">X_{27}< / annotation>< / semantics>< / com:Math> is E or absent, <com:Math><semantics>X28<annotation encoding="application / x-tex">X_{28}< / annotation>< / semantics>< / com:Math> is N or Y, <com:Math><semantics>X29<annotation encoding="application / x-tex">X_{29}< / annotation>< / semantics>< / com:Math> is K or R, <com:Math><semantics>X30<annotation encoding="application / x-tex">X_{30}< / annotation>< / semantics>< / com:Math> is A or D, <com:Math><semantics>X31<annotation encoding="application / x-tex">X_{31}< / annotation>< / semantics>< / com:Math> is T or S, <com:Math><semantics>X32<annotation encoding="application / x-tex">X_{32}< / annotation>< / semantics>< / com:Math> is V or A, <com:Math><semantics>X33<annotation encoding="application / x-tex">X_{33}< / annotation>< / semantics>< / com:Math> is G or D, <com:Math><semantics>X34<annotation encoding="application / x-tex">X_{34}< / annotation>< / semantics>< / com:Math> is T, I, or S, and <com:Math><semantics>X35<annotation encoding="application / x-tex">X_{35}< / annotation>< / semantics>< / com:Math> is T, S, or A; and (b) a VL region comprising the amino acid sequence of SEQ ID NO:62.
[00267] In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VH comprising an amino acid sequence as set forth in Table 7. In a specific embodiment, a MUC16 Glycosylation Antibody or antigen- binding fragment thereof described herein comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:1 (Table 7) (e.g., the VH of antibody 10C6). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:21 (Table 7) (e.g., the VH of antibody 7B12). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:41 (Table 7) (e.g., the VH of antibody 19C11). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:61 (Table 7) (e.g., the VH of antibody 16C5). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:81 (Table 7) (e.g., the VH of antibody 18C6).
[00268] In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a VL comprising an amino acid sequence as set forth in Table 8. In a specific embodiment, a MUC16 Glycosylation Antibody or antigen- binding fragment thereof described herein comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:2 (Table 8) (e.g., the VL of antibody 10C6). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:22 (Table 8) (e.g., the VL of antibody 7B12). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:42 (Table 8) (e.g., the VL of antibody 19C11). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:62 (Table 8) (e.g., the VL of antibody 16C5). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:82 (Table 8) (e.g., the VL of antibody 18C6).
[00269] In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a VH comprising an amino acid sequence as set forth in Table 7; and (b) a VL comprising an amino acid sequence as set forth in Table 8. In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:1 (Table 7) (e.g., the VH of antibody 10C6); and (b) a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:2 (Table 8) (e.g., the VL of antibody 10C6). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:21 (Table 7) (e.g., the VH of antibody 7B12); and (b) a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:22 (Table 8) (e.g., the VL of antibody 7B12). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:41 (Table 7) (e.g., the VH of antibody 19C11); and (b) a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:42 (Table 8) (e.g., the VL of antibody 19C11). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen- binding fragment thereof described herein comprises (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:61 (Table 7) (e.g., the VH of antibody 16C5); and (b) a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:62 (Table 8) (e.g., the VL of antibody 16C5). In a specific embodiment, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises (a) a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO:81 (Table 7) (e.g., the VH of antibody 18C6); and (b) a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO:82 (Table 8) (e.g., the VL of antibody 18C6).
[00270] In certain embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein comprises VH CDRs (e.g., as set forth in Table 1, 3, or 5) of a VH comprising the amino acid sequence as set forth in Table 7 and VL CDRs (e.g., as set forth in Table 2, 4, or 6) of a VL comprising the amino acid sequence as set forth in Table 8.
[00271] In certain embodiments, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may be described by its VH domain alone, or its VL domain alone, or by its three VH CDRs alone, or by its three VL CDRs alone. See, e.g., Rader C et al., (1998) PNAS 95: 8910-8915 which describes the humanization of the mouse anti-ανβ3 antibody by identifying a complementing light chain or heavy chain, respectively, from a human light chain or heavy chain library, resulting in humanized antibody variants having affinities as high or higher than the affinity of the original antibody. See also, Clackson T et al., (1991) Nature 352: 624-628 describing methods of producing antibodies that bind a specific antigen by using a specific VH domain (or VL domain) and screening a library for the complementary variable domains. See also, Kim SJ & Hong HJ, (2007) J Microbiol 45: 572-577 describing methods of producing antibodies that bind a specific antigen by using a specific VH domain and screening a library (e.g., human VL library) for complementary VL domains; the selected VL domains in turn could be used to guide selection of additional complementary (e.g., human) VH domains.
[00272] In certain embodiments, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may be a humanized antibody, for example, a humanized form of a rodent antibody. Humanized antibodies can be produced using a variety of techniques known in the art, including but not limited to, CDR-grafting (European Patent No. EP 239,400; International publication No. WO 91 / 09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), chain shuffling (U.S. Patent No. 5,565,332), veneering or resurfacing (European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology 28(4 / 5):489- 498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; and Roguska et al., 1994, PNAS 91:969-973), and techniques disclosed in, e.g., U.S. Pat. No. 6,407,213, U.S. Pat. No. 5,766,886, WO 9317105, Sandhu JS, Gene 150(2):409-10 (1994), Pedersen et al., J. Mol. Biol. 235(3):959-73 (1994), Couto et al., Cancer Res. 55(8):1717-22 (1995), Roguska et al., Protein Eng. 9(10):895 904 (1996), Baca et al., J. Biol. Chem. 272(16):10678-84 (1997), Couto et al., Cancer Res. 55 (23 Supp):5973s-5977s (1995), Caldas et al., Protein Eng. 13(5):353-60 (2000), Morea et al., Methods 20(3):267 79 (2000), and Tan et al., J. Immunol. 169:1119 25 (2002). See also U.S. Patent Pub. No. US 2005 / 0042664 A1 (Feb. 24, 2005).
[00273] In certain embodiments, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may be a composite human antibody. A composite human antibody can be generated by, e.g., designing variable region sequences from fragments of multiple human antibody variable region sequences in a manner that avoids T cell epitopes, thereby minimizing the immunogenicity of the resulting antibody (see, e.g., Baker et al., 2010, Self Nonself., 1(4):314-322; Bryson et al., 2010, BioDrugs, 24(1):1-8; and Jones et al., 2009, Methods Mol Biol., 525:405-23). Such antibodies can comprise human constant region sequences, e.g., human light chain and / or heavy chain constant regions.
[00274] In certain embodiments, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may be a deimmunized antibody. A deimmunized antibody is an antibody in which T-cell epitopes have been removed. Methods for making deimmunized antibodies have been described. See, e.g., Jones et al., Methods Mol Biol. 2009;525:405-23, xiv, and De Groot et al., Cell. Immunol. 244:148-153(2006)).
[00275] In specific embodiments, a MUC16 Glycosylation Antibody or antigen-binding fragment thereof described herein is a humanized immunoglobulin that comprises the 3 VH CDRs and the 3 VL CDRs (i.e., VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3) of any of the antibodies in Table 1, Table 2, and Table 3, and Table 4, Table 5, and Table 6, respectively, human-derived framework regions, and human derived constant regions. Non-limiting examples of human framework regions are described in the art, e.g., see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). In certain embodiment, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein comprises framework regions (e.g., framework regions of the VL domain and / or VH domain) that are human framework regions or derived from human framework regions. In certain embodiments, a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein comprises framework regions (e.g., framework regions of the VL domain and / or VH domain) that are primate (e.g., non-human primate) framework regions or derived from primate (e.g., non-human primate) framework regions. For example, CDRs from antigen-specific non-human antibodies, typically of rodent origin (e.g., mouse or rat), are grafted onto homologous human or non-human primate (e.g., Old World apes, e.g., Pan troglodytes, Pan paniscus or Gorilla gorilla, Pan troglodytes, Old World monkeys, e.g., from the genus Macaca, or the cynomolgus monkey Macaca cynomolgus). Non-human primate framework sequences are described in U.S. Patent Application Publication No. US 2005 / 0208625.
[00276] In a specific embodiment, the position of VH CDR1, VH CDR2, and / or VH CDR3 in the VH region and / or the position of VL CDR1, VL CDR2, and / or VL CDR2 in the VL region of a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may vary by 1, 2, 3, 4, 5, 6, or more amino acid positions so long as (i) immunospecific binding to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133 is maintained; (ii) lack of immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139 is maintained; and (iii) inhibition of matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16 is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%). In another embodiment, the length of VH CDR1, VH CDR2, and / or VH CDR3 in the VH region and / or the length of VL CDR1, VL CDR2, and / or VL CDR2 in the VL region of a MUC16 Glycosylation Antibody or antigen binding fragment thereof described herein may vary (e.g., be shorter or longer) by 1, 2, 3, 4, 5, 6, or more amino acids, so long as (i) immunospecific binding to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133 is maintained; (ii) lack of immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139 is maintained; and (iii) inhibition of matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16 is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%). In another embodiment, the amino terminus and / or the carboxy terminus of a VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and / or VL CDR3 described herein may be extended or shortened by 1, 2, 3, 4, 5, 6, or more amino acids compared to one or more of the CDRs described herein so long as (i) immunospecific binding to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133 is maintained; (ii) lack of immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139 is maintained; and (iii) inhibition of matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16 is maintained (e.g., substantially maintained, e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%). As used herein, the terms "immunospecifically binds," "immunospecifically recognizes," "specifically binds," and "specifically recognizes" are analogous terms in the context of antibodies and refer to antibodies and antigen-binding fragments thereof that bind to an antigen (e.g., epitope or immune complex) via the antigen-binding sites as understood by one skilled in the art, and does not exclude cross-reactivity of the antibody or antigen-binding fragment with other antigens. Any method known in the art can be used to ascertain whether (i) immunospecific binding to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133 is maintained; (ii) lack of immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139 is maintained; and (iii) inhibition of matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16 is maintained, e.g., ELISA binding assays or FACs analysis as described in Section 6, below.
[00277] In specific aspects, provided herein is a MUC16 Glycosylation Antibody or antigen- binding fragment thereof comprising an antibody heavy chain and / or light chain, e.g., a heavy chain alone, a light chain alone, or both a heavy chain and a light chain. With respect to the heavy chain, in a specific embodiment, the heavy chain of a MUC16 Glycosylation Antibody or an antigen-binding fragment thereof described herein can be an alpha (<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>), delta (<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), epsilon (<com:Math><semantics>ϵ<annotation encoding="application / x-tex">\epsilon< / annotation>< / semantics>< / com:Math>), gamma (<com:Math><semantics>γ<annotation encoding="application / x-tex">\gamma< / annotation>< / semantics>< / com:Math>) or mu (<com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>) heavy chain. In another specific embodiment, the heavy chain of a MUC16 Glycosylation Antibody or antigen binding fragment thereof described can comprise a human alpha (<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>), delta (<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), epsilon (<com:Math><semantics>ϵ<annotation encoding="application / x-tex">\epsilon< / annotation>< / semantics>< / com:Math>), gamma (<com:Math><semantics>γ<annotation encoding="application / x-tex">\gamma< / annotation>< / semantics>< / com:Math>) or mu (<com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>) heavy chain.
[00278] In a particular embodiment, a MUC16 Glycosylation Antibody or an antigen-binding fragment thereof described herein, which (i) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, which first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, which second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139; and (iii) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16, comprises a heavy chain wherein the amino acid sequence of the variable region of the heavy chain comprises a VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequences of SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:105, respectively, SEQ ID NO:109, SEQ ID NO:110, and SEQ ID NO:111, respectively, or SEQ ID NO:115, SEQ ID NO:116, and SEQ ID NO:117, respectively, and wherein the constant region of the heavy chain is a human alpha (<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>), delta (<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), epsilon (<com:Math><semantics>ϵ<annotation encoding="application / x-tex">\epsilon< / annotation>< / semantics>< / com:Math>), gamma (<com:Math><semantics>γ<annotation encoding="application / x-tex">\gamma< / annotation>< / semantics>< / com:Math>) or mu (<com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>) heavy chain constant region. As used herein, the term "constant region" or "constant domain" is interchangeable and has its meaning common in the art. The constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and / or heavy chain which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with the Fc receptor. The constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain. In a particular embodiment, a MUC16 Glycosylation Antibody or an antigen-binding fragment thereof described herein comprises a heavy chain wherein the amino acid sequence of the variable region of the heavy chain comprises a VH CDR1, VH CDR2, and VH CDR3 of antibody 10C6, 7B12, 19C11, 16C5, or 18C6 (i.e., those listed in Table 1, Table 3, or Table 5) and wherein the constant region of the heavy chain is a human alpha (<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>), delta (<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), epsilon (<com:Math><semantics>ϵ<an...
Claims
1. An antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment (a) immunospecifically binds to a cell recombinantly expressing a first form of MUC16, wherein the first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133, (b) lacks immunospecific binding to a cell recombinantly expressing a second form of MUC16, wherein the second form is unglycosylated, and wherein the amino acid sequence of the second form is SEQ ID NO:139, (c) inhibits matrigel invasion in vitro of cells recombinantly expressing said first form of MUC16, (d) lacks immunospecific binding to a cell recombinantly expressing a third form of MUC16, wherein the third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO:139, and (e) immunospecifically binds to the amino acid sequence CGTQLQNFTLDRSSV (SEQ ID NO:131), wherein amino acid residue number 7 (N7) of CGTQLQNFTLDRSSV (SEQ ID NO:131) is glycosylated.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein (i) the cell recombinantly expressing the first form of MUC16 is a SKOV3 cell; (ii) the cell recombinantly expressing the second form of MUC16 is a SKOV3 cell; and (iii) the cells in step (c) are SKOV3 cells.
3. The antibody or antigen-binding fragment thereof of claim 2, wherein the cell recombinantly expressing the third form of MUC16 is a SKOV3 cell.
4. The antibody or antigen-binding fragment thereof of any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof immunospecifically binds to the amino acid sequence CTRNGTQLQNFTLDRSSV (SEQ ID NO:130), wherein amino acid residue number 4 (N4) and amino acid residue number 10 (N10) of CTRNGTQLQNFTLDRSSV (SEQ ID NO:130) are glycosylated.
5. The antibody or antigen-binding fragment thereof of any one of claims 1-4, wherein the antibody or antigen-binding fragment thereof immunospecifically binds to an epitope comprising N-glycosylated asparagine 30 of SEQ ID NO: 133.
6. The antibody or antigen-binding fragment thereof of claim 4 or 5, wherein the glycosylation consists of an N-linked chitobiose.
7. The antibody or antigen-binding fragment thereof of any one of claims 1-6, wherein the antibody or antigen binding fragment inhibits growth of a tumor that expresses a glycosylated form of MUC16; or wherein the antibody or antigen-binding fragment thereof is internalized into a cell expressing the first form of MUC16 upon contacting the cell with the antibody or antigen- binding fragment, optionally wherein the cell that recombinantly expresses the first form of MUC16 is a SKOV3 cell.
8. The antibody or antigen-binding fragment thereof of any one of claims 1-7, wherein the antibody is a monoclonal antibody.
9. The antibody or antigen-binding fragment thereof of any one of claims 1-8, wherein the antibody or antigen-binding fragment thereof comprises (a) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88; or (b) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94; or (c) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100; or (d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28; or (e) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34; or (f) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40; or (g) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48; or (h) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54; or (i) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60; or (i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8; or (k) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14; or (l) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or ( m ) (m) ( i ) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68; or (n) (1) a VH comprising aVH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74; or (0) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
10. The antibody or antigen-binding fragment thereof of claim 9, wherein the antibody or antigen-binding fragment thereof comprises (a) (i) a VH comprising the amino acid sequence of SEQ ID NO:81; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:82; or (b) (i) a VH comprising the amino acid sequence of SEQ ID NO:1; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:2; or (c) (i) a VH comprising the amino acid sequence of SEQ ID NO:21; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:22; or (d) (1) a VH comprising the amino acid sequence of SEQ ID NO:41; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:42; or (e) (i) a VH comprising the amino acid sequence of SEQ ID NO:61; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:62.
11. An antibody or antigen-binding fragment thereof that immunospecifically binds to MUC16, wherein the antibody or antigen-binding fragment thereof comprises: (a) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:23, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:24, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:25; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:27, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:28; or (b) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:29, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:30, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:31; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:33, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:34; or (c) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:36, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:37; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:38, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:39, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:40; or (d) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:44, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:45; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:46, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:47, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:48; or (e) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:50, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:51; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:52, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:53, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:54; or (f) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:56, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:58, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:59, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:60; or (g) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:83, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:84, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:85; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:86, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:87, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:88; or (h) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:89, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:90, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:91; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:92, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:93, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:94; or (i) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:95, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:96, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:97 and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:98, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:99, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:100; or (j) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:5; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:6, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:7, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:8; or (k) (1) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:9, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:10, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:11; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:12, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:13, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:14; or (1) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:15, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:16, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:17; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:18, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:19, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or ( m ) (m) ( i ) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:63, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:65; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:66, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:67, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:68; or (n) (1) a VH comprising aVH CDR1 comprising the amino acid sequence of SEQ ID NO:69, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:70, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:71; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:72, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:73, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:74; or (0) (i) a VH comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:75, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:77; and (ii) a VL comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:79, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:80.
12. The antibody or antigen-binding fragment of claim 11, wherein the antibody or antigen-binding fragment thereof comprises (a) (1) a VH comprising the amino acid sequence of SEQ ID NO:1; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:2; (b) (1) a VH comprising the amino acid sequence of SEQ ID NO:21; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:22; or (c) (1) a VH comprising the amino acid sequence of SEQ ID NO:41; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:42; or (d) (1) a VH comprising the amino acid sequence of SEQ ID NO:61; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:62; or (e) (1) a VH comprising the amino acid sequence of SEQ ID NO:81; and (ii) a VL comprising the amino acid sequence of SEQ ID NO:82.
13. The antibody or antigen-binding fragment thereof of any one of claims 9-12, wherein the antibody comprises human-derived heavy and light chain constant regions, optionally wherein the heavy chain constant region has an isotype selected from the group consisting of gamma1, gamma2, gamma3, and gamma4 and / or the light chain constant region has an isotype selected from the group consisting of kappa and lambda.
14. The antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof is humanized or is a humanized form of a rodent antibody.
15. The antibody or antigen-binding fragment thereof of any one of claims 1-14, wherein the antibody is an immunoglobulin comprising two identical heavy chains and two identical light chains, optionally wherein the immunoglobulin is an IgG.
16. An antibody conjugate comprising the antibody or antigen-binding fragment thereof of any one of claims 1-15 conjugated to an agent, optionally wherein the agent is an imaging agent or a cytotoxic agent.
17. The antibody or antigen-binding fragment thereof of any one of claims 1-14, wherein the antibody or antigen-binding fragment thereof is a bispecific antibody, optionally wherein the bispecific antibody immunospecifically binds CD3.
18. The antibody or antigen-binding fragment of claim 17, wherein the bispecific antibody comprises a first immunoglobulin comprising two identical heavy chains and two identical light chains that immunospecifically binds MUC16, and a first single chain variable fragment (scFv) that immunospecifically binds CD3, wherein the light chains of the first immunoglobulin is conjugated via a peptide linker to the scFv.
19. A bispecific antibody conjugate comprising the bispecific antibody of claim 17 or 18 conjugated to an agent, optionally wherein the agent is an imaging agent or a cytotoxic agent.
20. The antibody or antigen-binding fragment thereof of any one of claims 1-12 or 14, wherein the antigen-binding fragment thereof is a scFv.
21. A scFv conjugate comprising the scFv of claim 20 conjugated to an agent, optionally wherein the agent is an imaging agent or a cytotoxic agent.
22. A chimeric antigen receptor (CAR) comprising: the antibody or antigen-binding fragment of any one of claims 1-15; or the scFv of claim 20.
23. A T cell which recombinantly expresses the CAR of claim 22.
24. A polynucleotide comprising nucleic acid sequences encoding a scFv comprising the antigen-binding fragment of any one of claims 9-12, or a CAR comprising the scFv or the antibody or antigen-binding fragment of any one of claims 9-12.
25. A vector comprising the polynucleotide of claim 24 operably linked to a promoter.
26. An ex vivo cell comprising one or more polynucleotides encoding the antibody or antigen-binding fragment thereof of any one of claims 9-13 operably linked to a promoter, the polynucleotide of claim 24 operably linked to a promoter, or the vector of claim 25.
27. A pharmaceutical composition comprising: a therapeutically effective amount of the antibody or antigen-binding fragment thereof of any one of claims 1-15, the antibody conjugate of claim 16, the bispecific antibody of any one of claims 17 or 18, the bispecific antibody conjugate of claim 19, the scFv of claim 20, the scFv conjugate of claim 21, the CAR of claim 22, or the T cell of clam 23; and a pharmaceutically acceptable carrier.
28. Use of the pharmaceutical composition of claim 27 for treating a MUC16-expressing cancer in a patient in need thereof.
29. The use of claim 28, wherein said MUC16-expressing cancer is a cancer of the lung, pancreas, breast, uterine, fallopian tube, or primary peritoneum.
30. The use of claim 28, wherein said MUC16-expressing cancer is a cancer of the ovary.
31. The use of any one of claims 28-30, wherein the pharmaceutical composition is formulated to be administrable with an additional therapeutic agent.
32. The use of claim 31, wherein the pharmaceutical composition comprises a therapeutically effective amount of a first antibody that is the antibody or antigen-binding fragment thereof of any one of claims 1-15, wherein the antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N-glycosylated Asn 30 of SEQ ID NO: 133 but does not comprise N-glycosylated Asn 24 of SEQ ID NO: 133; and wherein the additional therapeutic agent is a second antibody or antigen-binding fragment thereof, wherein the second antibody or antigen-binding fragment thereof recognizes an epitope in MUC16 that comprises N-glycosylated Asn 30 of SEQ ID NO: 133 and also comprises N-glycosylated Asn 24 of SEQ ID NO: 133.
33. The use of claim 32, wherein the first antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind a cell recombinantly expressing a first form of MUC16, wherein the first form of MUC16 is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO: 133; (ii) its lack of immunospecific binding to a cell recombinantly expressing a third form of MUC16, wherein the third form is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its ability to immunospecifically bind a cell recombinantly expressing a fourth form of MUC16, which fourth form is glycosylated, and wherein the amino acid sequence of the fourth form is SEQ ID NO: 152, wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same cell type, and wherein the second antibody or antigen-binding fragment thereof is identified by (i) its ability to immunospecifically bind to a cell recombinantly expressing a first form of MUC16, wherein the first form is glycosylated, and wherein the amino acid sequence of the first form is SEQ ID NO:133; (ii) its ability to immunospecifically bind to a cell recombinantly expressing a third form of MUC16, wherein the third form of MUC16 is glycosylated, and wherein the amino acid sequence of the third form is SEQ ID NO: 139; and (iii) its lack of immunospecific binding to a cell recombinantly expressing a fourth form of MUC16, which fourth form is glycosylated, and wherein the amino acid sequence of the fourth form is SEQ ID NO:152; and wherein the cell recombinantly expressing the first form of MUC16, the cell recombinantly expressing the third form of MUC16, and the cell recombinantly expressing the fourth form of MUC16 are of the same type of cell.
Citation Information
Patent Citations
Anti-muc16 antibodies and uses thereof
US62134402P0
